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ABSTRACT 
 
Protein arginine methyltransferase 1 (PRMT1) is a key posttranslational modification 
enzyme that catalyzes the methylation of specific arginine residues in histone and nonhistone 
protein substrates, regulating diverse cellular processes such as transcriptional initiation, RNA 
splicing, DNA repair, and signal transduction. Recently the essential roles of PRMT1 in cancer 
and cardiovascular complications have intrigued much attention. Developing effective PRMT 
inhibitors therefore is of significant therapeutic value. The research on PRMT inhibitor 
development however is greatly hindered by poor understanding of the biochemical basis of 
protein arginine methylation and lack of effective assays for PRMT1 inhibitor screening.  
Herein, we report our effort in the kinetic mechanism study as well as the fluorescent 
probe and inhibitor development for PRMT1. New fluorescent reporters were designed and 
applied to perform single-step analysis of substrate binding and methylation of PRMT1. Using 
these reporters, we performed transient-state fluorescence measurements to dissect the rate 
constants along the PRMT1 catalytic coordinate. The data give evidence that the chemistry of 
 methyl transfer is the major rate-limiting step, and that binding of the cofactor SAM or SAH 
affects the association and dissociation of H4 with PRMT1. Importantly, we identified a critical 
kinetic step suggesting a precatalytic conformational transition induced by substrate binding. On 
the other hand, we discovered a type of naphthyl-sulfo (NS) compounds that block PRMT1-
mediated arginine methylation at micromolar potency through a unique mechanism: they directly 
target the substrates but not PRMT enzymes for the observed inhibition. We also found that 
suramin, an anti-parasite and anti-cancer drug bearing similar functional groups, effectively 
inhibited PRMT1 mediated methylation. These findings about novel PRMT inhibitors and their 
unique inhibition mechanism provide a new way for chemical regulation of protein arginine 
methylation. Addionally, to dissect the interplaying relationship between different histone 
modification marks, we investigated how individual lysine acetylations and their different 
combinations at the H4 tail affect Arg-3 methylation in cis. Our data reveal that the effect of 
lysine acetylation on arginine methylation depends on the site of acetylation and the type of 
methylation. While certain acetylations present a repressive impact on PRMT-1 mediated 
methylation (type I methylation), lysine acetylation generally is correlated with enhanced 
methylation by PRMT5 (type II dimethylation). In particular, Lys-5 acetylation decreases 
activity of PRMT1 but increases that of PRMT5. Furthermore, hyperacetylation increases the 
content of ordered secondary structures of H4 tail. These findings provide new insights into the 
regulatory mechanism of Arg-3 methylation by H4 acetylation, and unravel that complex 
intercommunications exist between different posttranslational marks in cis.  
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CHAPTER 1 
INTRODUCTION 
1.1. The structure and function of chromatin 
Exclusively found in eukaryotic cells, chromatin is composed of regularly and intensively 
packed DNA and protein. ~146 bp DNA is wrapped around the histone octamer consisting of 
two of each of H3, H4, H2A and H2B proteins to form a fundamental repeating genetic element 
called nucleosome (Figure 1.1). As the smallest unit of genetic information storage, nucleosomes 
are linked by H1 protein and DNA to form compressed chromatin fibers with a beads-on-string 
structure. These ~30 nanometer fibers are further coiled into chromosome, which plays 
regulatory role in multiple nuclear processes like transcription, replication, DNA repair, mitosis 
and apoptosis.(1) The chromatin structure can be changed by epigenetic modifications of DNA 
and histones during different phases of cell division.(2-5)  
Chromatin is categorized into euchromatin and heterochromatin according to its 
conformation and staining state. Euchromatin is loosely packed and stains lightly, and is usually 
composed of actively transcribed genes. On the other hand, heterochromatin is tightly packed 
and stains intensly, and is mainly composed of inactive genes or satellite sequences, such as 
centromere and telomere. H3K9 di and tri-methylation are usually linked with heterochromatin 
structure [Zhang MQ et al, BMC Genomics, 2009]. 
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Figure 1.1. The structure and modification sites of nucleosome in chromatin (6) 
 
1.2. Histone posttranslational modifications  
Histones are the major protein components of chromatin, packaging DNA into 
nucleosome and helping regulate gene expression. Histones undergo extensive posttranslational 
modifications (PTMs) at its amino-terminal tail domain where lie multiple positively charged 
residues. Some of these modification sites have been detected by specific antibodies or tandem 
mass spectrometry,(7) including lysine acetylation/metylation, arginine methylation, serine 
phosphorylation, lysine ubiquitination, etc (Figure 1.2). These modifications represent enormous 
potential biological functions (Table 1.1).(8) For example, the residue Lys can be labeled with 
mono-, di-, or trimethyl group by various lysine methyltransferases; while the residue Arg can be 
marked with mono-, asymmetric di- or symmetric di-methyl group by different protein arginine 
methyltransferases (PRMTs).(9, 10) Many of these PTMs profoundly affect the on-and-off status 
of gene transcription by recruiting other modulator proteins or factors to initiate the downstream 
transcriptional activation or repression. Notably, the specificity of methylation may lead to 
3 
 
 
distinct biological functions, e.g., H3 K4 or K27 methylation (mono-, di-, or tri-) activates 
transcription, but H3 K9 methylation (di- or tri-) represses transcription.(11) The molecular 
mechanism by which histone PTMs modulate genetic and epigenetic processes is not fully 
understood. In particular, how a PTM mark affects the presence and level of other histone 
modification marks needs to be addressed and is essential for better understanding the molecular 
basis of histone code hypothesis. 
 
ARTKQTARKSTGGKAPRKQLATKAARKSAPATGGVKK-
SGRGKGGKGLGKGGAKRHRKC-
SGRGKQGGK-
PEPAKSAPAPKKGSKKAVTK-
K --- Acetylation
K --- Acetylation and methylation
K --- Ubiquitination
R, K --- Methylation
S, T --- Phosphorylation
H3
H4
H2A -K119
H2B -K123
 
Figure 1.2. Post-translational modifications on histone N-terminal tail domains 
 
Table 1.1. Different types of histone modifications 
Modification Residue Function Related disease Typical enzyme 
Acetylation Lys Transcription, 
Repair 
Cancer p300, pCAF, 
Tip60(12) 
Methylation Lys, Arg Transcription, 
Repair, Splicing 
Cancer, 
Cardiovascular disease 
PRMT1, PRMT5 
(13) 
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Phosphorylation Ser, Thr Transcription, 
Repair 
Cancer MSK1(14) 
Ubiquitylation Lys Transcription, 
Repair 
Cancer E1(15) 
Sumoylation Lys Transcription, 
Nuclear transport 
 SAE1/SAE2(16) 
 
1.3. Histone arginine methylation 
Posttranslational modifications (PTMs) are important strategies used by eukaryotic 
organisms to modulate their phenotypes. One of the well studied PTMs, arginine methylation, is 
catalyzed by protein arginine methyltransferases (PRMTs) with SAM as the methyl donor. The 
functions of PRMTs have been broadly studied in different biological processes and diseased 
states, but the molecular basis for arginine methylation is not well defined. 
Taking Histone H4 arginine 3 (H4R3) methylation as an example, asymmetric 
dimethylation of H4R3 mediated by PRMT1 leads to gene activation, while symmetric 
dimethylation of H4R3 mediated by PRMT5 is related to gene repression. The two enzymes 
introducing these modifications exhibit identifiably similar sequences, but the molecular bases 
for their distinct catalytic mechanisms are unclear. A recent report suggested that a conserved 
phenylalanine in the active site of PRMT5 is critical for directing the symmetric di-methylation. 
(17) It has also been shown that asymmetric dimethylation at H3R17 by CARM1 enhances 
transcription activation, that symmetric dimethylation at H3R8 by PRMT5 induces transcription 
repression, and that asymmetric dimethylation at H3R2 by PRMT6 leads to gene repression and 
is mutually exclusive with H3K4 methylation.  
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1.4. Protein arginine methyltransferases 
Protein arginine methyltransferases (PRMTs) belong to an important family of 
posttranslational modification enzymes that transfer the methyl group from AdoMet (S-adenosyl 
methionine, SAM) to specific arginine residues in histone or nonhistone protein substrates. Thus 
far, eleven PRMT members have been identified and are categorized into two major types, type I 
and type II, according to the substrate and product specificity.(18-20) Type I enzymes (PRMT-1, 
-2, -3, -4, -6, and -8) catalyze the transfer of the methyl group from AdoMet to one of the 
terminal nitrogen atoms of the guanidino group of specific arginine residues in a protein 
substrate, resulting in ω-NG-monomethylarginine (MMA, L-NMMA) and ω-NG,NG-asymmetric 
dimethylarginine (ADMA) products.(19, 21-24) Type II enzymes (e.g., PRMT 5, 7, and 9) 
catalyze the formation of MMA and ω-NG, N’G-symmetric dimethylarginines (SDMA).(24-27) 
A more recent report demonstrated PRMT7 as a Type III enzyme forming only MMA.(28) The 
catalytic properties of PRMT-10, and -11 remain to be characterized.  
 
 
 
 
 
 
 
 
Figure 1.3. Scheme of protein arginine methylation 
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TYPE   Histone specifity
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Figure 1.4. Protein arginine methyltransferasenine family members expressed in human. 
Black: conserved catalytic domain. SH3: The SRC homology 3 domain. Zn2+: Zinc finger 
binding domain. F box: encoding a protein motif of ~ 50 amino acids as a site of protein-protein 
interaction. 
 
Protein arginine methylation is involved in a broad spectrum of biological processes, 
including transcriptional activation and repression, mRNA splicing, nuclear─cytoplasmic 
shuttling, DNA repair, and signal transduction.(29) The variety of PRMTs’ cellular activities is 
partly due to their diverse substrate profiles, including RNA binding proteins (hnRNPa, 
fibrillarin, nucleolin, etc.), high molecular weight fibroblast growth factor 2 (HMW FGF-2), 
7 
 
 
interleukin enhancer binding factor 3 (ILF3), and histone H3 and H4. Each PRMT enzyme 
(PRMT1-9) has a specific set of substrates that partially overlap with the substrates of another 
family member. The specificity of PRMTs is demonstrated by the fact that only particular 
arginine residues out of all the arginines in a protein substrate are the target methylation sites. 
The substrate specificity of PRMTs is determined by the structure of its active site and 
peptide binding grooves. PRMT enzymes are composed of a variable N-terminus and a 
conserved catalytic core; PRMT4 (CARM1) also contains a unique C-terminal region. So far the 
crystal structures of PRMT1, PRMT3 and PRMT4 (CARM1) are available, which are all type I 
PRMTs that catalyze the formation of monomethylated and asymmetrically dimethylated 
arginines.  
1.5. Protein arginine methyltransferase 1 (PRMT1) 
PRMT1 is the predominant type I protein arginine methyltransferase in mammals. 
Human PRMT1 gene is located on chromosome 19 (Location: 19q13.3). The protein contains 
352 amino acids (AAH19268.2; GI:32425330). There is only one amino acid difference between 
human and rat PRMT1, that is, the Tyr161 in hPRMT1 is replaced with His in rPRMT1. Since 
His still bears similar aromatic property as Tyr, we can say that PRMT1 is highly conserved 
between human and rat species. 
The methylation sites in PRMT1 substrates usually fall into RGG or RXR clusters 
contained within the Gly and Arg rich (GAR) domains. That means the methylation area is of 
multiple positive charges. Zhang and Cheng (30) reported the crystal structure of rPRMT1 bound 
with product SAH (S-adenosyl homocysteine) and substrate peptide R3 
(GGRGGFGGRGGFGGRGGFG). PRMT1 monomer consists of an N-terminus, a SAM binding 
domain, a barrel-like domain, and a dimerization arm, with the active site pocket lying between 
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the two catalytic core domains (Figure 1.5A). The AdoMet binding domain adopts a rossmann 
fold structure that is conserved in other SAM-dependent methyltransferases. SAH is bound in a 
deep pocket formed by five parallel β strands. The interactions include the Van der Waals 
contacts between G78 and G80 backbone and SAH homocysteine and adenosine ribose, the 
bifurcated H-bonds between E100 and the ribose hydroxyl groups, and the H-bond between 
E129 and the amino group of adenine. Besides, R45 forms salt bridges between the carboxylate 
group of homocysteine and the active site residue E144, and His 45 interacts with one of the 
ribose hydroxyl groups through H-bond. The N-terminal helix αX helps to constrain the bound 
SAH. The barrel-like domain is special to PRMT family. Several conserved residues between the 
two core domains make up the active site, and form a hairpin between strand β4 and helix αD. 
Two conserved glutamates - E144 and E153 on this “double-E loop” hydrogen bond the 
guanidine group, while the Y148 aromatic ring lies parallel to the hydrophobic methylene groups 
of the target arginine (Figure 1.5B). E153Q mutation completely abolished methylation activity, 
while E144Q mutation reduced the activity by 3000 fold, indicating that these two negatively 
charged glutamates are critical for catalysis. It is proposed that the two invariant glutamates fix 
the positive charge on the guanidine group on the δ and one of the ω nitrogens, so that the lone 
pair of electrons left on the other ω nitrogen can attack the active methylsulfonium group of 
SAM in close proximity. The attacking guanidine nitrogen is deprotonated by a His-Asp relay 
system. Therefore the active site pH environment can affect the stability of positively charged 
transition state and thus the catalytic effecity. This puts electrostatic and steric requirements for 
the residues besides the target arginine. 
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Figure 1.5. Strucutres of hPRMT1 and rPRMT1. A. Predicted 
structure of hPRMT1 monomer. Structure prediction is made by 
Dr. Harrison’s structure and alignment web server based on the 
crystal structure of protein 1ORHA and is visualized with 
RasMol 2.7.5. The red color indicates the catalytic group Glu153. 
The green color indicates the human to rat mutant (Tyr to His) residue, which should be Tyr161 
here. B. Reported structure of rPRMT1(E153Q) (PDB/1ORH). Figure made with RasMol 2.7.5. 
The bound substrate Arginine and product SAH (Sulfur displaced in spacefill to show its close 
proximity with the terminal nitrogen of Arg) are shown in green; The E153Q mutant and H162 
are shown in blue. C. Reported active site structure of rPRMT1 with bound Arginine. (30) 
 
PRMT1 functions as dimer or oligomer, as the ∆ARM mutant completely lost catalytic 
activity, probably because it is unable to bind SAH properly. The dimer interface is formed 
A B
Rossmann fold domain Beta-barrel domain 
AdoMet binding site 
Arg binding site 
Dimerization Arm 
C 
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between the outer surface of Adomet binding domain and the dimerization arm. Acid residues 
(20 Asp and Glu) are predominant on the surface of PRMT1, forming several acid grooves which 
are supposed to generate an initial binding affinity for positively-charged arg substrates. Surface-
scannng mutagenesis study indicated that some of these negatively charged residues were 
important for substrate specificity (E47, E129, and E236), substrate binding (E46 and D51), 
dimerization/oligomerization, or transcription coactivator function (31). In the crystal structure, 
the electron densities of bound peptide substrates were broken into three separate fragments 
(Figure 1.6). Other than the arginine bound in the active site, the amino acid residues of the 
peptide were not clearly identified due to low resolution of side chain densities. A mixture of 
peptide binding modes was proposed from the three disconnected densities. The fact multiple 
substrate binding grooves exist on the surface of PRMT1 may explain why PRMT1 methylates 
diverse protein substrates. The negatively charged C terminus is close to the active site and may 
play an important role for substrate binding or catalysis.  
 
 
Figure 1.6. Structure of Ternary Complex of PRMT1-AdoHcy-R3 Peptide.  (30) A. 
Molecular surface of PRMT1 with bound AdoHcy and Arg. P1, P2, and P3 are three peptide 
A B 
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binding sites. B. Two side views of A showing the three peptide binding sites and other acidic 
grooves. 
 
The crystal structures of PRMT3 and PRMT1 are very similar, with the only difference 
(beside N terminus) in β barrel domain - a single residue deletion and an eight-residue insertion; 
yet the structure of CARM1 shows significant difference in the β barrel, the helix-turn-helix of 
the dimerization arm, and the C-terminal extension which is not present in other PRMTs (32). 
The crystal structures of the apo and holo CARM1 catalytic core suggested that SAH binding 
induces a structural change forming a substrate binding channel for the access of arginine to the 
active site. The N-terminal helices αX and αY, and the first eight residues of the unique C-
extension of CARM1 participate in supporting the groove. The central cavity of CARM1 dimer 
is much larger than that of PRMT1 or PRMT3 dimer, presumably to accommodate the C-
extension. CARM1 with deleted C-extension failed to methylate H3 Arg17. Additionally, 
CARM1 possesses a less acidic surface (only five acidic residues). These may be the reasons 
why CARM1 methylates a different and smaller substrate profile including histone H3, 
p300/CBP and several RNA-binding proteins that lack the highly basic GAR domain or any 
consensus motif. But again as high resolusion electron density for a bound peptide in the 
complex structure is unavailable, the features and specificity subsites within the substrate 
binding groove that can determine the selective recognition of residues flanking the target 
arginine haven’t been revealed yet.  
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Figure 1.7. Proposed kinetic mechanisms of PRMT1(33) 
Several studies of the kinetic mechanism of arginine methylation have been recently 
reported. Dr. Thompson’s group suggested that PRMT1 utilizes a rapid equilibrium random 
mechanism (RER) for methyl transfer with the formation of dead-end EAP and EBQ complexes 
(33). However, Dr. Frankel’s group showed that PRMT6 follows an ordered sequential 
mechanism in which SAM binds to the enzyme first and the methylated product is the first to 
dissociate (34). The different results in these two studies suggest that kinetics of arginine 
methylation can vary slightly among the individual isoforms. 
1.6. The study points in this work 
1.6.1. The development of fluorescent peptide probes for PRMT1 
PRMTs play important roles in normal physiology and human diseases. Simple, rapid, 
non-radioactive, colorimetric/fluorescent assays are particularly needed for the enzymatic 
study of PRMTs and for the identification of potent PRMT inhibitors. The design of non-
radioactive PRMT assays, however, is technically challenging because the substrates and 
products of PRMTs exhibited little spectroscopic difference.(35) Recently, several coupled 
13 
 
 
colorimetric and fluorescent methods are reported to study SAM-dependent 
methyltransferases, including PRMTs. In these methods, the enzymatic methylation reaction 
is carried out in conjugation with secondary enzymes that convert SAH to adenine and then 
hypoxanthine, a spectrometrically active compound,(35) or to homocysteine which is 
subsequently detected by thiol-reactive chromogenic/fluorogenic compounds.(36-38) The 
major advantage of the coupled methods is that they avoid using radioisotope-labeled 
materials and allow for the measurement of PRMT activity via absorption or fluorescent 
readouts. However, these methods involve multiple additional components which may 
potentially complicate the methylation results. Especially, when used for inhibitor screening, 
there is a high chance that the coupling components may be intervened thus leading to 
positive hits. Therefore, new alternative methods are highly demanded to serve as research 
tools to ecluidate the functions of PRMTs in health and disease as well as to facilitate the 
discovery of PRMT inhibitors. Thus we tried to design and evaluate a fluorescent competitive 
binding assay of PRMT1 for both basic kinetic analysis and inhibition study. The fluorescent 
displacement strategy is particularly useful to probe PRMT-substrate interactions, and thus 
finding application in screening organic inhibitors that target the substrate-binding pocket of 
PRMTs. Importantly, by applying this method, we elucidated the inhibitory mode of AMI-1, a 
potent PRMT inhibitor, the mechanism of which was unknown. 
To create the fluorescent reporters that can be used for non-radioactive PRMT binding 
assay, we synthesized fluorescein-labeled peptides based on two different substrates of 
PRMT1. First, PRMT1 and several other PRMT members are reported to robustly methylate a 
number of GAR motifs which frequently occur in RGG repeats of proteins such as fibrillarin 
and nucleolin.(23, 39) Herein, we synthesized a fluorescent GAR-rich peptide (R4-FL) which 
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contains a fluorescein labeling on a lysine residue. In addition, PRMT1 was previously shown 
to methylate histone H4 at the R3 residue.(26, 40, 41) In this case, we used a fluorescein-
labeled H4 peptide, H4-FL,(42) based on the N-terminal 20-aa sequence of histone H4. The 
fluorescein group was linked at position 10 through a 2,3-diaminopropionic acid residue 
(Dpr). Fluorescein was selected as the reporter group because it has long absorption and 
emission wavelengths and its photophysical properties are relatively sensitive to local 
microenvironment. We rationalized that fluorescent signals (e.g., intensity, anisotropy) 
change accordingly when these small peptide ligands bind to and/or are methylated by 
PRMT1, and that when the interaction between PRMT1 and the ligand is disrupted, there is a 
recovery of fluorescent signal. 
1.6.2. The inhibition study of PRMT1 
Given the essential roles that PRMTs play in normal biology and in disease, quite a few 
efforts have been invested in developing small molecule PRMT inhibitors both as chemical 
genetic tools and as therapeutic agents.(43-45) The first type of chemical inhibitors for PRMTs 
are analogues of the AdoMet cofactor, including S-adenosylhomocysteine (SAH), 
methylthioadenosine, and sinefungin.(44) Due to structural similarities to AdoMet, these 
analogue inhibitors target all AdoMet-consuming methyltransferases, such as DNA 
methyltransferases, protein lysine methyltransferases, and O-methyltransferases. In the past few 
years, several groups reported their work in a row on developing small molecule inhibitors 
specific for PRMTs. Most of these studies on PRMT inhibitor discovery adopted targeted or 
random screening approaches. The screening strategy is so widely accepted largely because of 
technical advancement in computer-aided drug design and in medium- and high-throughput 
inhibitor screening. Thus far, the disclosed small molecule PRMT inhibitors include 1 (AMI-
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1),(46) stilbamidine and allantodapsone,(47) the thioglycolic amide RM65,(48) pyrazole amide 
compounds,(49) and others.(50-54) It is important to point out that past inhibitor development 
efforts were mostly focused on inhibition of the enzyme, presumably, through binding to the 
active site. This is also the case with the vast majority of enzyme inhibition work reported related 
to other enzymes so far. Because a single PRMT catalyzes the methylation of arginine residues 
in multiple proteins, inhibition of a particular PRMT inevitably results in bulky inhibition of 
methylations of a large number of proteins, but not on a particular substrate sequence. Herein, we 
report a type of compounds that block PRMT1-mediated arginine methylation at micromolar 
potency through a unique mechanism. Most of the discovered compounds bear naphthalene and 
sulfonate groups and are structurally different from typical PRMT substrates, e.g., histone H4 
and glycine- and arginine-rich sequences. To elucidate the molecular basis of inhibition, we 
conducted a variety of kinetic and biophysical assays. The combined data reveal that this type of 
naphthyl-sulfo (NS) molecules directly targets the substrates but not PRMTs for the observed 
inhibition. We also found that suramin effectively inhibited PRMT1 activity. These findings 
about novel PRMT inhibitors and their unique inhibition mechanism provide a new way for 
chemical regulation of protein arginine methylation. 
1.6.3. The transient-state kinetics and catalytic mechanism of PRMT1 
Transient state is at the very beginning of a reaction when the enzyme and the substrate is 
trying to meet each other and the concentration of reactive E-S complex and the reaction rate are 
changing as a function of time. It occurs before steady state when the formation and breakdown 
of E-S complex reach an equilibrium and the maximum reaction rate is constant with time. 
The functions of PRMTs have been broadly studied in different biological processes and 
diseased states, but the molecular basis for arginine methylation is not well defined. Many 
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important questions about the PRMT-catalyzed arginine methylation reaction remain to be 
answered. For instance, it is not known whether the chemical step or a protein conformational 
change in the ES complex is rate-limiting for catalysis. Such a molecular level understanding of 
how substrate recognition is coupled to catalysis will be of great significance to evaluate the 
function of PRMT activity in different physiological contexts. To address these mechanistic 
questions, transient kinetic analyses of arginine methylation are highly desirable. Unfortunately, 
such studies are greatly limited by lack of assay tools appropriate for fast measurement of 
substrate binding and methylation on rapid time-scales. Here we studied the transient-state 
kinetic analysis of PRMT1 catalysis using stopped-flow fluorescence measurement with 
fluorescein-labeled peptide substrates. The fast association and dissociation rates suggest that 
PRMT1 catalysis of histone H4 methylation follows a rapid equilibrium sequential kinetic 
mechanism. The data give direct evidence that the chemistry of methyl transfer is the major rate-
limiting step, and that binding of the cofactor SAM or SAH affects the association and 
dissociation of H4 with PRMT1. Importantly, from the stopped-flow fluorescence 
measurements, we have identified a critical kinetic step suggesting a precatalytic conformational 
transition induced by substrate binding. These results provide new insights into the mechanism 
of arginine methylation and the rational design of PRMT inhibitors. 
1.6.4. The interaction between lysine acetylation and arginine 3 methylation on H4 tail 
It has become an increasing recognition that multiple PTM marks at the amino-terminal 
tails of the core histones intercommunicate with one another to fundamentally regulate DNA 
functions such as transcription, replication, recombination and damage repair (5, 55). At the 
molecular level, how  individual PTM patterns or codes are created and how they affect 
downstream molecular events are poorly defined. More studies are needed to address the 
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communicational relationship between functionally related histone modification marks. 
Acetylation of H4 at its N-terminal tail is commonly seen in many cell types. With 16 possible 
acetylation combinations, cells may benefit by utilizing such combinatorial modification tricks to 
fine tune and/or maximize multivalent readouts for diversified functionality. In this study, we 
investigated in detail the impact of individual acetylation marks at K5, 8, 12, 16, and their 
different combinations on type I and type II methylation at site R3. It was previously shown that 
H4 acetylation reduced PRMT1-mediated R3 methylation (40). However, it is not clear how 
individual acetylations combinatorially affect R3 methylation and which acetylation site plays a 
predominant role in affecting R3 methylation. Furthermore, R3 can be either asymmetrically 
dimethylated or symmetrically dimethylated. It remains unknown whether lysine acetylation 
affects these two types of methylation in the same or distinct manners. To answer these 
mechanistic questions, we created a library of H4 peptides containing all the possible acetylated 
isoforms. The concentration of each peptide was calibrated with NMR to obtain the accurate 
concentration prior to the enzymatic methylation experiments. Our data reveal that the effect of 
lysine acetylation on arginine methylation depends on the site of acetylation and the type of 
methylation. While certain acetylations bring a repressive impact on PRMT-1 mediated 
methylation, lysine acetylation generally is correlated with enhanced methylation by PRMT5. 
Furthermore, circular dichroism study and computer simulation demonstrate that 
hyperacetylation increases the content of ordered secondary structures at the H4 tail region. 
These findings provide new insights into the regulatory mechanism of Arg-3 methylation by H4 
acetylation, and unravel that complex intercommunications exist between different PTM marks 
in cis. The divergent activities of PRMT1 and PRMT5 with respect to different acetyl-H4 
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substrates suggest that type I and type II PRMTs use distinct molecular determinants for 
substrate recognition and catalysis. 
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CHAPTER 2 
INHIBITORY STUDY OF PROTEIN ARGININE METHYLTRANSFERASE 1 USING A 
FLUORESCENT APPROACH 
(This work is mainly based on the published paper Biochem. Biophys. Res. Commun. 379 (2009) 
567-72. In this project, the author is obliged to Dr. Nan Xie, Dr. Jiang Wu, and Chao Yang for 
their great contributions to peptide preparation.) 
2.1. Introduction 
Protein arginine methylation has emerged as an important regulatory mechanism for gene 
expression and cellular signalling (18-20). The methylation is catalyzed by protein arginine 
methyltransferases (PRMTs) that transfer the methyl group from S-adenosyl-L-methionine 
(AdoMet, SAM) to specific arginine residues in histone and nonhistone protein substrates, 
resulting in mono and di-methylated arginine residues and S-adenosyl-L-homocysteine 
(AdoHcy, SAH). It has been shown that PRMTs are involved in the regulation of diverse 
biological processes such as DNA transcription, RNA processing, DNA repair, and cell 
differentiation (24, 56-58). As the predominant PRMT protein in mammalian cells, PRMT1 
(HRMT1L2) accounts for 85% of cellular PRMT activity (59). Notably, deregulation of PRMT1 
has been linked to certain diseases such as breast cancer and leukaemia (60, 61), which suggests 
its role as a potential drug target. 
Rapid, homogeneous, nonradioactive, and colorimetric or fluorescent assays are 
particularly needed for the kinetic analysis of PRMTs and for the identification of potent PRMT 
inhibitors. The design of nonradioactive PRMT assays, however, is technically challenging 
because the substrates and products of PRMTs exhibited little spectroscopic difference (35). 
Recently, several coupled colorimetric and fluorescent methods were reported to study SAM-
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dependent methyltransferases, including PRMTs. In these methods, the enzymatic methylation 
reaction is carried out in conjugation with secondary enzymes that convert SAH to adenine and 
then hypoxanthine, a spectrometrically active compound (35), or to homocysteine which is 
subsequently detected by thiol-reactive chromogenic or fluorogenic compounds (36-38). The 
major advantage of the coupled methods is that they avoid using radioisotope-labeled materials 
and allow for the measurement of PRMT activity via absorption or fluorescent readouts. 
However, these methods involve multiple additional components which may potentially 
complicate the methylation results. Especially, when used for inhibitor screening, there is a high 
chance that the coupling components may also be inhibited thus leading to false positives. 
Therefore, new and alternative methods are highly needed to serve as research tools to ecluidate 
the functions of PRMTs in health and disease as well as to facilitate the discovery of PRMT 
inhibitors. 
In this paper, we report our work of designing peptide-based fluorescent reporters and 
using them for biochemical analysis and inhibition study of PRMT1. These fluorescent ligands 
are proved to be effective to probe PRMT-substrate interaction with dual modes of fluorescence 
intensity and fluorescence anisotropy, thus suited for studying organic inhibitors that target the 
substrate-binding pocket of PRMTs. By applying the fluorescent reporters in combination with 
radioactive methylation assay, we elucidated the inhibitory mechanism of AMI-1, the first 
reported small molecule PRMT inhibitor (46). 
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2.2. Results and discussion 
2.2.1. Expression and purification of PRMT1 
6×His-tagged rat PRMT1 was successfully expressed with BL21(DE3) and purified by 
Ni affinity chromatography. As shown in Figure 2.1, a major band of relatively pure PRMT1 was 
obtained, which can be used directly in the kinetic study. 
 
                  1           2              3           4            5             6             7             8 
 
 
Figure 2.1. SDS-PAGE of rPRMT1 after purification 
1. Marker. 2. 70 mM imidazole washing. 3. Beads before elution. 4. 200 mM imidazole 
eluant1. 5. 200 mM imidazole eluant2. 6. 200mM imidazole eluant3. 7. 200 mM imidazole 
eluant4. 8. Beads after elution.  
2.2.2. Design and synthesis of the fluorescent PRMT1 reporters  
To create the fluorescent reporters that can be used for nonradioactive PRMT study, we 
synthesized fluorescein-labeled peptides based on two different substrates of PRMT1. First, 
PRMT1 and several other PRMT members are reported to robustly methylate glycine and 
PRMT1 
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arginine-rich (GAR) motifs which frequently occur in RGG repeats of proteins such as fibrillarin 
and nucleolin (23, 39). Herein, we made a fluorescent GAR-rich peptide (R4-FL) which is 
labeled with fluorescein through a lysine residue (Table 2.1). Apart from methylating GAR 
motifs, PRMT1 also methylates histone H4 at the R3 site (26, 40, 41). We synthesized a labeled 
H4 peptide, H4-FL (42), by modifying the N-terminal 20-aa sequence of histone H4 with 
fluorescein at position 10 through a 2,3-diaminopropionic acid residue (Dpr). Fluorescein was 
selected as the reporter group because it has long absorption and emission wavelengths and its 
photophysical properties are relatively sensitive to the local microenvironment. We envisioned 
that the fluorescent signals (e.g., intensity, anisotropy) of fluorescein might change accordingly 
when the peptide ligands bind to and/or are methylated by PRMT1. Synthesis of these peptidyl 
compounds was achieved using the Fmoc-based solid phase peptide synthesis protocol. 
Table 2.1. Sequences of H4, H4-FL, R4, and R4-FL 
Peptide Sequence Expected mass Observed mass
H4 Ac-SGRGKGGKGLGKGGAKRHRK 2034.4 2034.1 
H4-FL Ac-SGRGKGGKGDpr(FL)GKGGAKRHRK 2366.7 2366.4 
R4 Ac-GGRGGFGGRGGKGGRGGFGGRGGFG 2223.4 2223.2 
R4-FL Ac-GGRGGFGGRGGK(FL)GGRGGFGGRGGFG 2582.4 2581.3 
 
2.2.3. Fluorescence response of the PRMT1 reporters 
We first tested whether the fluorescence intensity of fluorescein can change upon ligand-
enzyme interaction. His6x-tagged recombinant rat PRMT1 was expressed in E. coli and purified 
on Nickel-NTA beads. As shown in Figure 2.2, the fluorescence intensity of both H4-FL and R4-
FL decreases at increasing concentrations of rPRMT1. The magnitude of the change at the 
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maximum emission wavelength (524 nm) is approximately 25%. Such a fluorescence intensity 
change most likely reflects that the microenvironment surrounding the fluorescein group is 
altered after ligand-PRMT1 binding. The molecular factors causing such alteration may include 
hydrophobicity variation, prototropic shift, and the presence of new hydrogen bonding with 
PRMT1 (62, 63). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Fluorescence intensity changes of H4-FL and R4-FL upon interaction 
with PRMT1. (a) Emission spectra obtained for H4-FL (0.20 μM) with increasing 
concentrations (0, 0.05, 0.10, 0.15, 0.20, and 0.30 μM) of PRMT1. (b) Plot of the fluorescence 
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intensity of H4-FL at 524 nm as a function of PRMT1 concentration. (c) Emission spectra 
obtained for R4-FL (0.20 μM) with increasing concentrations (0, 0.05, 0.25, 0.84, 1.25, and 2.57 
μM) of PRMT1. (d) Plot of the fluorescence intensity of R4-FL at 524 nm as a function of 
PRMT1 concentration. 
 
It is an intriguing question whether the reporter molecules can be used to probe the 
catalytic process of PRMT1. To investigate this possibility, we mixed R4-FL with PRMT1 in the 
presence of AdoMet and monitored the fluorescence emission at 524 nm at different time points. 
As shown in Figure 2.3, the fluorescence intensity of R4-FL first decreases rapidly and then 
gradually goes up. It is quite likely that the first phase (i.e. the rapid fluorescence decrease) 
corresponds to substrate binding and the second phase (i.e. the gradual fluorescence increase) 
corresponds to the methyl transfer and/or product release. A detailed stopped flow study will 
reveal more information about this complex process. To our knowledge, this is the first example 
of reporting a simple fluorescent approach that can be used to examine the pre-steady state 
kinetics of PRMT catalysis. Interestingly, the analog inhibitor, sinefungin, is only able to inhibit 
the methylation step, suggesting that its inhibition of PRMT1 is not competitive against the 
peptide substrate. 
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Figure 2.3. Inhibition Effect of Sinefungin on PRMT1 methylation. 
B: 0 μM sinefungin, C: 5μM sinefungin, D: 15 μM sinefungin, E: 50 μM sinefungin. 0.4 μM of 
PRMT1 is added to the mixed solution of R4-FL (0.2 μM) and Sinefungin (0 μM, 5 μM, 15 μM 
or 50 μM). The dropping curve shows the binding of R4-FL and PRMT1, and the raising curve 
shows the methylation of R4-FL.  
 
We next examined the fluorescence anisotropy of H4-FL and R4-FL in the presence of 
PRMT1. It is expected that, when bound to PRMT1, the molecular mobility of the organic 
ligands will be in a more restricted state due to the complex formation, which will give rise to 
larger anisotropy readouts. Indeed, our data showed that the fluorescence anisotropy of both H4-
FL and R4-FL increases as a function of PRMT1 concentration (Figure 2.4). The maximal 
magnitudes of the anisotropy enhancement are 100% and 300% for H4-FL and R4-FL, 
respectively, which are much larger than that of the fluorescence intensity change. Thus, the 
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fluorescence anisotropy or polarization of H4-FL and R4-FL is better suited than fluorescence 
intensity for use in screening PRMT1 inhibitors. It should be noted that the dynamic range in 
anisotropy could be further increased by using recombinant PRMT1 that contains more bulky 
tags such as GST or by reducing the size of the reporter ligands. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Fluorescence anisotropy titration. (a) Fluorescence anisotropy (524 nm) of 
H4-FL solution at different PRMT1 concentrations. The concentration of H4-FL is 0.20 μM. The 
Kd is calculated to be 0.31 ± 0.04 μM. (b) Fluorescence anisotropy (524 nm) of R4-FL solution 
at different PRMT1 concentrations. The concentration of R4-FL is also 0.20 μM. The Kd is 
calculated to be 0.40 ± 0.07 μM. 
 
A minor concern is that the added fluorophore might interfere with the interaction of H4 
and R4 peptides with PRMT1, thus compromising the methylation reaction. To investigate this 
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effect, we measured the steady state kinetic parameters of PRMT1 for both the labeled and non-
labeled peptides. 14C-labeled AdoMet was used as the methyl donor in the assay. The methylated 
products were loaded onto P81 paper and quantified by scintillation counting. As shown in Table 
2.2, the Km of H4-FL and R4-FL, respectively, doubled that of H4 and R4, while the kcat values 
decreased by half. The largest effect was only a 3-4 fold difference in the specificity constants 
(V/K). The comparisons of these kinetic parameters suggest that the attached fluorescein group 
moderately affects the methylation of the peptide substrates by PRMT1, and overall, these 
labeled ligands are still reasonably good substrates of PRMT1. 
 
Table 2.2. Steady state kinetic parameters of rPRMT1 in the methylation of H4, R4 
and their fluorescent derivatives. The concentration of PRMT1 and AdoMet is 0.01 μM and 30 
μM, respectively. 
substrate Km, μM kcat, min-1 kcat/Km, min-1 μM -1 
H4 0.64 ± 0.04 0.81 ± 0.01 1.27 ± 0.08 
H4-FL 1.14 ± 0.13 0.43 ± 0.01 0.38 ± 0.04 
R4 0.90 ± 0.06 0.69 ± 0.01 0.77 ± 0.05 
R4-FL 1.84 ± 0.56 0.45 ± 0.05 0.24 ± 0.08 
 
2.2.4. Inhibitory study of AMI-1 using the fluorescent strategy 
After having assessed the fluorescent responses of H4-FL and R4-FL upon interaction 
with PRMT1, we applied the reporters to probe the interaction of PRMT1 with AMI-1, the first 
reported small-molecule PRMT inhibitor that was discovered by Bedford and co-workers.(46) 
AMI-1 inhibits several PRMTs (PRMT1,-3,-4,-6 and Hmt1p) and bears no similarity to AdoMet 
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analogues. The mechanism by which AMI-1 inhibits the enzymatic activity of PRMTs is still not 
identified. Due to certain structural similarity to peptidyl arginine, it was speculated that AMI-1 
may bind to the substrate-binding pocket of the PRMT enzymes (46), but a recent docking study 
suggested that AMI-1 might interact with residues of the AdoMet binding pocket (48). To 
elucidate the inhibitory mode of AMI-1, we examined the interaction of AMI-1 with PRMT1 
using our fluorescent reporters. As shown in Figure 2.5, the fluorescence anisotropy of both H4-
FL/PRMT1 and R4-FL/PRMT1 mixtures decreases at increasing concentrations of AMI-1, 
indicating that the fluorescent ligands are displaced from binding to PRMT1 by the inhibitor. 
The inhibition constant (Ki) of AMI-1 in these two competitive assays is calculated to be 15.8 ± 
3.5 μM and 19.8 ± 3.1 μM, respectively, using the method of Nikolovska-Coleska, et al.(64) 
This evidence demonstrates that AMI-1 targets the same binding pocket in PRMT1 with the H4 
and R4 substrates. It also suggests that histone H4 and RGG-rich substrates may bind to PRMT1 
in a similar structural manner. 
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Figure 2.5. Competitive inhibition assays of AMI-1 against H4-FL (a) and R4-FL (b) 
using the mode of fluorescence anisotropy. The reporter and PRMT1 concentration is 2.00 μM 
and 4.00 μM for H4-FL assays and 0.20 μM and 2.00 μM for R4-FL assay. 
 
To further substantiate the inhibitory mode of AMI-1, we investigated the inhibition 
pattern of AMI-1 versus AdoMet and the peptide substrates using radioisotopic assay. Initial 
velocities of PRMT1 were determined, and the data were plotted in double-reciprocal form with 
E/velocity versus 1/[H4], 1/[R4], and 1/[AdoMet], respectively, at several fixed concentrations 
of AMI-1 (Figure 2.6). The results show that AMI-1 is a linear competitive inhibitor versus H4 
(and also R4, data not shown), while is noncompetitive (mixed type) versus AdoMet. The Ki of 
AMI-1 from the competitive kinetic assay (Figure 2.6a) is calculated to be 17.7 μM, which is 
consistent with the results obtained from the fluorescence anisotropy competitive binding 
measurement. These data indicate that AMI-1 competes with the protein/peptide substrate, but 
not AdoMet, for the same form of PRMT1 and the same mutually exclusive binding site, thus 
further validating the conclusion that AMI-1 inhibits the methylase activity of PRMT1 by 
blocking the access of protein/peptide substrates. 
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Figure 2.6. Inhibition pattern analysis of AMI-1 to PRMT1 plotted as reciprocal 
plots. a. E/V versus 1/[H4] at fixed AdoMet (5 μM) and varying AMI-1: 0 μM (♦), 50 μM ( ), 
100 μM (  ), and 200 μM (x). The inhibition plot of AMI-1 against R4 was similar to that of H4 
and is not shown. b. E/V versus 1/[AdoMet] at fixed H4 (2 μM) and varying AMI-1: 0 μM (♦), 
50 μM ( ), and 100 μM (  ).  
There are several valuable merits about the fluorescent competitive binding assay 
developed herein. First, it is simple, thus avoiding complications caused by using coupling 
components. Second, this displacement strategy is geared to target compounds that block PRMT-
substrate interaction, which is directly associated with methylase activity. Since GAR motif-
containing sequence is a known common feature of substrates for many PRMTs,(23) R4-FL is 
not only a fluorescent reporter of PRMT1, but will be applicable to other PRMT members as 
well. Third, since the assay is independent of the enzymatic activity, the strength of the 
methylase activity of PRMTs does not directly influence the assay. This catalytic activity-
a b
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independent feature is particularly important for PRMTs since many recombinant PRMT 
enzymes exhibited very weak methylase activities, so that it is difficult to characterize the PRMT 
enzymatic reaction in a practical manner. For example, recombinant mouse PRMT4/CARM1 
also methylates a RGG-repeat sequence,(65) but its activity is so low that no adequate readable 
signals would be produced using a coupled assay method within regular assay time frame 
(usually less than one hour). Therefore, although the fluorescence anisotropy/intensity 
measurement is not a direct detection of PRMT enzymatic activity, our strategy complements 
and offers unique advantages over the current PRMT assay toolkits, and will be particularly 
useful to study and screen potent PRMT inhibitors. 
2.3. Conclusion 
We demonstrated the use of single fluorophore-labeled reporters to examine the substrate 
binding and methylase activity of PRMT1. This method will be of wide application in studying 
protein-substrate interactions and in screening PRMT inhibitors. By combining the fluorescent 
assay with radioactive measurement, we established the inhibitory mechanism of AMI-1; i.e., it 
inhibits the enzymatic activity of PRMT1 by dislodging protein/peptide substrates out of the 
binding pocket in the enzyme. Furthermore, we showed that the fluorescence intensity of R4-FL 
is sensitive to the progression of both substrate binding and methylation, suggesting that it will 
be a useful fluorescent probe to investigate the transient kinetic mechanism of PRMT catalysis.  
2.4. Experimental 
2.4.1. Synthesis of the fluorescent reporters. 
Solid Phase peptide synthesis (SPPS) was performed on a PS3 peptide synthesizer 
(Protein Technologies) using the Fmoc (N-(9-fluorenyl) methoxycarbonyl) strategy. Fmoc-
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protected amino acids, Rink amide resin and Pre-loaded Wang resin were purchased from 
NovaBiochem. All the synthetic reactions were performed at room temperature unless indicated 
otherwise. Removal of Fmoc was performed with 20 % v/v piperidine/DMF. For the coupling of 
each amino acid (AA), 4 eq. of AA/HBTU/HOBt (N-Hydroxybenzotriazole) were used. N-
methylmorpholine (NMM) was used as the catalytic base. The N-terminal amino group was 
acetylated with Ac2O unless indicated otherwise. The Dde (dimethyldioxocyclohexylidene) 
group on the lysine residue was removed with a solution of 2% hydrazine in DMF (66), and then 
the free amino group reacted with fluorescein-OSu for fluorophore labeling. After solid phase 
synthesis, the resins were subsequently washed with DMF, dichloromethane and then dried in 
vacuum for at least 2h before cleavage. Peptides were cleaved from resin by treatment with 95% 
TFA, 2.5% H2O and 2.5 % triisopropylsilane (handling of TFA must be performed in a secure 
hood) for 3-4h. Cold ether was used to precipitate the products. Crude products were collected 
by centrifugation and were washed with cold diethyl ether. After lyophilization, the compounds 
were re-dissolved in water and purified with reverse-phased (RP) HPLC (C18, Varian) on a 
Varian Prostar HPLC system using linear gradients of H2O/0.05% TFA (solvent A) vs. 
acetonitrile/0.05% TFA (solvent B). Analytical HPLC and MALDI-MS were used for 
characterization. 
2.4.2. Enzymatic methylation assay. 
Recombinant His6x-tagged rat PRMT1 enzyme was expressed using a pET28b vector in 
E. coli and purified on nickel-NTA beads. The methylation buffer contained 50 mM HEPES (pH 
= 8.0), 0.5 mM DTT, 1 mM EDTA, and 50 mM NaCl. Methylation assays of H4 and R4 were 
carried out in 0.5 mL plastic tubes at 30°C with a reaction volume of 30 μL. To measure the 
kinetic parameters, the concentration was 10 nM for PRMT1 enzyme and 30 μM for 14C-AdoMet 
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(GE Healthcare), and the concentration of peptide ranged from 0 to 20 μM. Reactions were 
initiated with PRMT1 after the other components were incubated at 30°C for 5 min. The reaction 
was quenched by loading the mixtures onto the surface of a P81 filter paper disc. After washing 
and drying the paper, the amount of product was quantified by liquid scintillation. The inhibition 
pattern analysis of AMI-1 was determined by measuring initial velcotities of PRMT1 at different 
concentrations of one substrate, a fixed concentration of the second substrate, and selected 
concentrations of AMI-1. The data were displayed in double reciprocal format and fitted to 
competitive or noncompetitive kinetic equations (67). 
2.4.3. Fluorescence assay 
The fluorescence intensity and anisotropy were measured using a Fluoro-Max 4 
fluorimeter (Horiba Jobin Yvon). The buffer was the same as that of the radioactive assay. A 450 
μL reaction mixture with 0.2 μM H4-FL or R4-FL was made in a 0.5 mL plastic tube and 
incubated at 30 °C in the chamber for 5 min. Then increasing amount of PRMT1 was added 
while keeping the reporter concentration constant. The fluorescence spectra of each sample were 
taken and the temperature of the sample chamber was maintained at 30 °C throughout the 
measurement. The excitation wavelength was chosen at 498 nm, the emission wavelength ranged 
from 500 nm to 650 nm, and the excitation and emission slit widths were both set at 2 nm. The 
wavelength of maximum emission was found to be 524 nm for both fluorescein-labeled peptides. 
The maximum fluorescence intensity data at 524 nm was extracted and plotted as a function of 
PRMT1 concentration. For the kinetic fluorescent methylation analysis of R4-FL by PRMT1 and 
the effect of sinefungin, a mixture containing 0.2 μM R4-FL, 15 μM AdoMet and varied 
concentrations of sinefungin (0 μM, 5 μM, 15 μM, and 50 μM) was prepared and incubated at 30 
°C for 5 min, then, 0.4 μM of PRMT1 was added and fluorescence intensity was monitored at 
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different time points. The kinetic curves were normalized to the same starting point for 
comparison. Fluorescence anisotropy was tested under similar conditions as described above. 
The excitation wavelength was fixed at 498 nm and the emission wavelength was selected as 524 
nm (slit 2, 2 nm). Fluorescence anisotropy at 524 nm was acquired at different concentrations of 
PRMT1 and the data were fitted to a quadratic equation as a function of PRMT1 concentration. 
The inhibition effect of AMI-1 was analyzed using fluorescence anisotropy titration in similar 
conditions. For H4-FL assay, the peptide and PRMT1 concentrations were fixed at 2 μM and 4 
μM respectively; For R4-FL assay, they were fixed at 0.2 μM and 2 μM respectively. Increasing 
concentrations of AMI-1 were added for both assays until saturation was reached. 
 
 
 
 
 
35 
 
 
CHAPTER 3 
DISCOVERY AND MECHANISTIC STUDY OF A CLASS OF PROTEIN ARGININE 
METHYLATION INHIBITORS 
(This work is mainly based on the published paper, J. Med. Chem. 53 (2010)6028-39. In this 
project, the author is obliged to Dr. Mingyong Li and Dr. Binghe Wang for their great 
contributions to inhibitor virtual screening.) 
3.1. Introduction 
Among different post-translational modifications, arginine methylation is catalyzed by 
protein arginine methyltransferases (PRMTs), which utilize the cofactor S-adenosyl-L-
methionine (AdoMet, SAM) as a methyl donor. Thus far, eleven PRMT members have been 
identified and are categorized into two major types, type I and type II, according to the substrate 
and product specificity.(18-20) Type I enzymes (e.g., PRMT-1, -2, -3, -4, -6, and -8) catalyze the 
transfer of the methyl group from AdoMet to one of the terminal nitrogen atoms of the guanidino 
group of specific arginine residues in a protein substrate, resulting in ω-NG-monomethylarginine 
(MMA, L-NMMA) and ω-NG,NG-asymmetric dimethylarginine (ADMA) products.(19, 21-24) 
Type II enzymes (e.g., PRMT 5, 7, and 9) catalyze the formation of MMA and ω-NG, N’G-
symmetric dimethylarginines (SDMA).(24-27) The catalytic properties of PRMT-10, and -11 
remain to be characterized. Protein arginine methylation is involved in a broad spectrum of 
biological processes, including transcriptional activation and repression, mRNA splicing, 
nuclear─cytoplasmic shuttling, DNA repair, and signal transduction.(29) 
In recent years, the significance of PRMTs in human diseases is being increasingly 
recognized. As the predominant PRMT member, PRMT1 is likely to be responsible for bulk 
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protein arginine methylation in mammalian cells. Aberrant expression of spliced forms of 
PRMT1 has been observed in several tumor states, including breast cancer(61, 68) and colon 
cancer.(69, 70) Deregulation of the methylation of histone H4 at R3 (a major cellular substrate of 
PRMT1) is a suggestive marker of prostate cancer.(71) PRMT1 was recently shown to be a 
component of Mixed Lineage leukemia (MLL) transcription complex and the activity of PRMT1 
is required for malignant transformation.(60) PRMT4 (better known as CARM1) is 
overexpressed in both aggressive prostate cancer and breast tumor.(72, 73) The type-II PRMT 
member, PRMT5, is recruited to the promoters of tumor suppressor genes such as ST7 and 
NM23, and its overexpression was observed in a variety of lymphoma and leukemia cells,(18, 
74) in gastric carcinoma,(75) and in immortalized fibroblast cells.(76) In cardiovascular 
disorders, PRMT activity is associated with the up-regulation of serum ADMA, which 
subsequently blocks NO production and causes many cardiovascular implications such as 
diabetes and hypertension.(77-79) Furthermore, a number of viral proteins have been shown to 
be substrates of PRMTs, such as the herpes simplex virus 1 nuclear regulatory protein ICP27, the 
hepatitis C virus protein NS3, the Epstein-Barr virus nuclear antigen 2, adenovirus E1BAP5 and 
L4-100K, and the HIV-1 proteins Rev, Tat, and the nucleocapsid protein.(23, 29) Together, these 
multiple lines of evidence point toward the extensive roles of PRMTs in human pathogenesis and 
suggest that PRMT inhibitors could be very useful research tools and be of pharmacological 
merits for disease intervention. 
Given the essential roles that PRMTs play in normal biology and in disease, quite a few 
efforts have been invested in developing small molecule PRMT inhibitors both as chemical 
genetic tools and as therapeutic agents.(43-45) The first type of chemical inhibitors for PRMTs 
are analogues of the AdoMet cofactor, including S-adenosylhomocysteine (SAH), 
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methylthioadenosine, and sinefungin.(44) Due to structural similarities to AdoMet, these 
analogue inhibitors target all AdoMet-consuming methyltransferases, such as DNA 
methyltransferases, protein lysine methyltransferases, and O-methyltransferases. In the past few 
years, several groups reported their work in a row on developing small molecule inhibitors 
specific for PRMTs. Most of these studies on PRMT inhibitor discovery adopted targeted or 
random screening approaches. The screening strategy is so widely accepted largely because of 
technical advancement in computer-aided drug design and in medium- and high-throughput 
inhibitor screening. Thus far, the disclosed small molecule PRMT inhibitors include 1 (AMI-
1),(46) stilbamidine and allantodapsone,(47) the thioglycolic amide RM65,(48) pyrazole amide 
compounds,(49) and others.(50-54) It is important to point out that past inhibitor development 
efforts were mostly focused on inhibition of the enzyme, presumably, through binding to the 
active site. This is also the case with the vast majority of enzyme inhibition work reported related 
to other enzymes so far. Because a single PRMT catalyzes the methylation of arginine residues 
in multiple proteins, inhibition of a particular PRMT inevitably results in bulky inhibition of 
methylations of a large number of proteins, but not on a particular substrate sequence. Herein we 
report our discovery of a class of inhibitors that modulate PRMT-mediated reaction through 
binding to the substrates, thus revealing a new way of chemical modulation of PRMT activities.  
3.2. Results and discussion 
3.2.1. Screening for new PRMT1 inhibitors 
In an effort to discover potent and selective PRMT1 inhibitors, we conducted a virtual 
screening to search for novel PRMT1 inhibitors from the ChemBridge small molecule compound 
collection (about 0.4 million compounds) using the reported crystal structure of rat PRMT1.(80) 
Briefly, the 2D structures of individual compounds were first converted into 3D structures by 
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using the CONCORD program(81) and then docked to the PRMT1 structure (PDB entry: 1OR8) 
using DOCK 6 program.(82) From this virtual screening, fifty compounds with high consensus 
scores were selected and experimentally tested for PRMT1 inhibition (see Table SI-1 in the 
supplementary information). In a typical radioactive experimental assay, a reaction mixture 
contained 0.1 μM of recombinant His6x-PRMT1, 5 μM of [14C]-labeled AdoMet, and 2 μM of 
the amino-terminal tail peptide of histone H4, i.e., H4(1-20), as the substrate, and was incubated 
at 30°C in the presence or absence of 100 μM of individual compounds. The retained fractional 
activity of PRMT1 was used as a parameter to evaluate the potency of the compounds in 
blocking PRMT1-mediated methylation. It is notable to mention that, for all the enzymatic 
assays, the methylation reaction is maintained under initial condition so that the reaction yields 
of the limiting substrates are lower than 10%, which is to ensure that the concentrations of 
AdoMet and peptide substrate do not decrease significantly over the time course of methylation 
reaction. The experimental assays, unfortunately, showed that the accuracy of the virtual 
screening was rather poor. Out of the fifty tested compounds, only one weak hit, 2 (#5252870, 
ChemBridge product ID), was found to show inhibition potency at IC50 about 1 mM. 
Subsequently, we searched for structural analogues of 2 from the ChemBridge small molecule 
collection to examine if more potent inhibitors can be found. Thirty-one compounds that bear 
similar structures or functional groups with 2 were selected and radioactive methylation assays 
were performed to evaluate this second set of compounds for inhibition of PRMT1 (Figure 3.1 
and Figure SI-1). From the test, nine compounds were identified to have inhibition activity 
against PRMT1 and their IC50 values ranged from 12 to 867 μM (Table 3.1). Interestingly, we 
noticed that some of the tested inhibitors bear great structural similarity to 1, a previously 
reported PRMT1 inhibitor by Bedford’s group.(46) All these compounds have rigid, planar, 
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conjugated systems, and contain one or more naphthalene aromatic rings. It is also recognized 
that most of them have negatively charged sulfonate groups and polar hydroxyl groups. Herein, 
we name these compounds as 3 (NS-1), 4 (NS-2), 5 (NS-3) and so on because of their 
characteristics of possessing naphthalene and sulfo groups. We also compared the inhibition 
potencies of these inhibitors with several PRMT1 inhibitors recently reported in the literature, 
including 1, stilbamidine and allantodapsone. As shown in Table 3.1, stilbamidine (IC50 = 105.7 
μM) exhibited comparable inhibition activity with 1 (IC50 = 137.1 μM). The inhibition potency 
of the other PRMT1 inhibitors, including allantodapsone, and compound 5756663 and 7280948 
reported in the literature,(47, 50) is even weaker. For example, at 2 mM of these three 
compounds, still 45%, 87%, and 100% of PRMT1 activity retains, respectively. By contrast, the 
NS-series of compounds identified here are quite stronger PRMT1 inhibitors. Four of these 
inhibitors, i.e., 3, 4, 5, and 6 (NS-4), showed stronger potency than 1 and stilbamidine. In 
particular, 3 exhibited the best inhibition potency with an IC50 of 12.7 μM, which is about ten-
fold lower than that of 1 and stilbamidine under the same reaction condition. 
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Figure 3.1. Structures of selected PRMT1 inhibitors 
Table 3.1. Inhibition of PRMT1 by selected compounds. 
IC50 values of different NS compounds were tested in the radioactive inhibition assays with 2 
μM of H4(1-20) or R4, 5 μM of [14C]-AdoMet, 0.1 μM of PRMT1, and increasing 
concentrations of each inhibitor. 
Compounds  IC50 (μM) for H4(1-20) 
methylation 
IC50 (μM) for R4 
methylation 
3 12.7 ± 0.1 741.7 ± 75.0 
4 43.1 ± 1.0 108.4 ± 8.4 
5 72.1 ± 1.0 463.1 ± 99.2 
6 104.2 ± 3.9 227.8 ± 7.8 
7 205.9 ± 25.2 1200 ± 16 
8 234.1 ± 10.1 595.8 ± 37.5 
9 280.6 ± 27.1 No inhibition at 2 mM 
41 
 
 
10 325.0 ± 36.9 No inhibition at 2 mM 
11 867.4 ± 13.6 No inhibition at 2 mM 
stilbamidine 105.7 ± 0.7 1150 ± 33 
1 137.1 ± 12.1 375.6 ± 7.8 
suramin 5.33 ± 0.23 1011 ± 20 
 
 
3.2.2. The kinetic pattern of PRMT1 inhibition by 3. 
To provide the biochemical basis of PRMT inhibition by this type of NS compounds, we 
investigated the inhibition mechanism of 3, the most potent inhibitor in the series. First, we 
performed a fluorescence anisotropy binding assay to check if the inhibitor can compete with the 
PRMT1 substrates. In this experiment, a fluorescein-labeled amino-terminal H4 peptide, namely 
H4(1-20)FL, with the sequence of Ac-SGRGKGGKGDpr(FL)GKGGAKRHRK, was used as a 
substrate ligand for PRMT1 binding.(83) The anisotropy of H4(1-20)FL increased upon binding 
to PRMT1, due to formation of a large macromolecular PRMT1-ligand complex (Figure 3.2). A 
Kd value of 0.49 ± 0.10 μM was calculated. Addition of 3 led to reversal of the anisotropy 
change, thus offering direct evidence that 3 is a competitive inhibitor versus the peptide 
substrate. Ki of 3 was deduced to be 1.71 ± 0.54 μM by fitting the titration data using the 
DynaFit program.(84) Similar competitive binding between 3 and a fluorescently labeled 
glycine- and arginine-rich (GAR) substrate, R4FL was also observed (Figure SI-2). To further 
validate the results of competitive inhibition, we conducted steady-state kinetic characterization. 
The initial velocities of PRMT1 were measured at several selected concentrations of the inhibitor 
over a range of varied concentrations of one substrate while fixing the concentration of the other. 
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The data were plotted in the double reciprocal fromat with 1/velocity versus 1/(concentration of 
the varied substrate) (Figure 3.3). The kinetic inhibition data points were analyzed by fitting to 
the linear competitive or noncompetitive inhibition equations.(67) As can be seen from the 
double-reciprocal plots, a series of straight lines intersected on the 1/velocity ordinate when the 
concentrations of H4(1-20) are varied, while the intersecting point moved to the western side of 
the ordinate when concentrations of AdoMet are varied. These data clearly demonstrate that 3 is 
competitive versus the peptide substrate and noncompetitive versus the methyl donor. This result 
is consistent with the fluorescent binding assay, and is also in agreement with our previous report 
showing that 1 is competitive versus peptide substrates and noncompetitive versus AdoMet.(83) 
In addition, 6, another inhibitor in this class, also exhibited the same inhibition pattern (Figure 
SI-3 and Figure SI-4b). These combined results support that this type of naphthalene-sulfo 
derivatives target PRMT1 by blocking the access of the substrate to the PRMT1 active site. 
Interestingly, the positively charged stilbamidine also showed competitive binding pattern in 
respect to the peptide substrate (Figure SI-4a), which is consistent with a previous report.(47)  
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Figure 3.2. Competitive binding measurement with fluorescence anisotropy. (a) 
Fluorescence anisotropy of H4(1-20)FL at different concentrations of PRMT1. The 
concentration of H4(1-20)FL was fixed at 0.2 μM. Kd of H4(1-20)FL to PRMT1 was calculated 
to be 0.49 ± 0.10 μM. (b) Fluorescence anisotropy (524 nm) of H4(1-20)FL and PRMT1 
complex at different concentrations of 3. The concentrations of H4(1-20)FL and PRMT1 were 
kept constant at 0.2 μM and 2.0 μM, respectively. Ki of 3 was calculated to be 1.71 ± 0.54 μM 
by fitting the titration data with DynaFit program. 
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Figure 3.3. Kinetic analysis of PRMT1 inhibition by 3. a. Double-reciprocal plotting of 
initial velocities versus varied concentrations of H4(1-20). The concentration of [14C]-AdoMet 
was fixed at 5 μM and the concentration of 3 was selected at 0 μM (♦), 5 μM (▲), 10 μM (■) 
and 20 μM(●). b. Double-reciprocal plotting of initial velocities versus varied concentrations of 
[14C]-AdoMet. The concentration of H4(1-20) was fixed at (2 μM) and the concentration of 3 
a  b
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was selected at 0 μM (♦), 5 μM (■) and 10 μM (▲). 0.03 μM of His6x-rPRMT1 was used in all 
these assays. 
 
3.2.3. Selectivity of 3. 
It is of interest to examine whether the NS inhibitors target PRMT1 selectively or also 
inhibit other PRMT members. Using radioactive methylation assays, we measured inhibitory 
activities of 3, the most potent compound in this series, towards PRMT3, PRMT4/CARM1, and 
PRMT6 (Table 3.2). The inhibition potency of 3 for GST-tagged hPRMT1 is similar to that for 
His6x-rPRMT1, with an IC50 of 12.9 ± 0.2 μM. PRMT3 was inhibited at a lower IC50 of 7.1 μM. 
At the concentration of 500 μM, 3 showed no apparent inhibitory effect to CARM1 (5μM of 
CARM1, 1 mM of H3(1-31), 30 μM of SAM). The IC50 for PRMT6 is about three-fold larger 
than that for PRMT1. It is worth mentioning that PRMT1 and PRMT3 share similar substrate 
specificity both of which methylate H4 and GAR peptides. On the other hand, CARM1 exhibits 
distinct substrate specificity from PRMT1. CARM1 targets H3 but does not methylate GAR 
sequences.(23) Therefore, the variation in inhibition potency is likely caused either by the 
differences between CARM1 and PRMT1 structures, or by the distinct nature of the substrates 
used. Overall, 3 inhibits PRMT1 and PRMT3 stronger than CARM1 and PRMT6. 
Table 3.2. Comparison of the inhibition of PRMT-1, -3, -4, and -6 by Compound 3. 
Data obtained from the results of the radioactive methylation assays. For the inhibition of His6x-
rPRMT1 or GST-hPRMT1, 2 μM of H4(1-20), 5 μM of [14C]-SAM and 0.1 μM of enzyme were 
used. For the inhibition of His6x-PRMT3, 2 μM of R4, 5 μM of [14C]-SAM and 0.1 μM of 
enzyme were used. For the inhibition of GST-CARM1, 1 mM of H3(1-31), 30 μM of [14C]-SAM 
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and 5 μM of enzyme were used. For the inhibition of His6x-PRMT6, 10 μM of H3(1-31), 5 μM 
of [14C]-SAM and 0.5 μM of enzyme were used.  
 
 Peptide substrate and its Km (μM) IC50 (μM) of 3 
His6x-rPRMT1 H4(1-20); 0.64 ± 0.04 12.7 ± 0.1 
GST-hPRMT1 H4(1-20); 0.69 ± 0.04 12.9 ± 0.2 
His6x-PRMT3 R4;0.92 ± 0.15 7.1 ± 0.2 
GST-CARM1 H3(1-31); 796 ± 204 ~ 2 mM 
His6x-PRMT6 H3(1-31); 9.1 ± 1.2 39.2 ± 2.8 
 
3.2.4. 3 directly targets the substrates, but not PRMT1. 
One paradox question is that the NS-series of inhibitors bear none or little structural 
similarity to the arginine-containing substrates of PRMT1 such as histone H4 or GAR peptides. 
In particular, all the reported PRMT1 substrates are rich in positive residues, i.e., arginines 
and/or lysines. The crystal structure of PRMT1 also reveals several large acidic grooves present 
at the protein surface which have been proposed to participate in the recognition of 
substrates.(80) On the other hand, most of the NS compounds are negatively charged due to the 
existence of one or more sulfonate groups. Therefore, it seems difficult to envision that 3 and its 
analogues will bind to PRMT1 at the same site as that of substrates in order to explain the 
competitive nature between the inhibitor and the peptide substrates. To look into these paradox 
problems, we hypothesized that 3 and its analogue inhibitors might bind to the PRMT1 substrate 
directly and that the binding subsequently prevents the substrate from accessing to PRMT1. 
Under this scenario, inhibitor-substrate interaction is likely facilitated by the electrostatic 
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interaction between the negatively-charged sulfonate groups and the cationic arginine guanidino 
group, as well as the van der Waals interaction between the naphthalene ring and the 
hydrophobic side chains in the substrate. It is conceivable that such interaction may shield the 
key motifs in the substrate so that they are not recognized by enzyme. To nail down the 
mechanistic details, we conducted several biophysical measurements to detect inhibitor-substrate 
and inhibitor-enzyme association. 
The interaction between the inhibitors and the PRMT1 substrate was confirmed by 
several experiments. First, when mixing high concentrations of H4(1-20) and 3 or 1 (e.g., 100 
μM of peptide and 200 μM of inhibitor), a red or brown precipitate occurred immediately. We 
reasoned that the precipitation is a strong indication of the association between H4 substrate and 
the inhibitors. The precipitate was pelleted by centrifugation, washed with water, dissolved in 
5% TFA, and analyzed with MALDI-MS. Indeed, the mass spectra revealed a peak 
corresponding to H4(1-20)—1 complex (Figure 3.4). We could not observe a peak for the H4(1-
20)—3 complex on MS spectra, probably due to the instability of H4(1-20)—3 and/or the strong 
anionic nature of 3. 
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Figure 3.4. Association of 1 with H4(1-20) peptide detected by MALDI-MS.  100 μM 
of H4(1-20) and 200 μM of 1 were mixed in the reaction buffer. The precipitate formed was 
pelleted by centrifugation, washed with H2O, dissolved in 5% TFA, and analyzed by MALDI-
MS. 
 
Next, we examined UV-Vis spectra of 3 in the presence of different concentrations of 
H4(1-20) or PRMT1 (Figure 3.5). 3 has a maximum absorption at 498 nm with extinction 
coefficient of 0.0182 μM-1cm-1. When H4(1-20) was gradually added to a solution of 3 (3 
concentration was kept constant at 40 μM), the absorbance decreased dramatically. For instance, 
at 10 μM of H4(1-20), the absorbance at 498 nm decreased to 25% of the original value. By 
contrast, the presence of PRMT1 had a quite minor effect on the absorption of 3. At 10 μM of 
PRMT1, the absorbance of 3 at 498 nm still retained 83%. These data directly pointed out that 
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the interaction between 3 and H4(1-20) is much stronger than 3—PRMT1 interaction, if there is 
any. 
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Figure 3.5. UV-Vis spectral change of 3 upon the addition of H4(1-20) or His6x-
PRMT1. 40 μM of 3 was titrated with 0 μM (red), 5 μM (blue) and 10 μM (green) of H4(1-20) 
(a) or PRMT1 (b). 
 
We then measured the fluorescence emission of H4(1-20)FL in the presence of 3. Since 
the absorption band of 3 overlaps with the fluorescence emission peak of H4(1-20)FL, it is 
anticipated that fluorescence energy transfer from fluorescein (donor) to 3 (acceptor) will occur 
if the two molecules form a complex. Indeed, addition of the inhibitor quenched the fluorescence 
emission of H4(1-20)FL (Figure 3.6). On the other hand, in the control experiment, addition of 
the inhibitor to a fluorescein solution caused little change to its fluorescence spectra (after 
removing the inner filter effect). These data demonstrate that the interaction between the 
inhibitor and H4(1-20)FL depends on the H4 peptide itself, instead of being caused by the 
a b 
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attached fluorescein label. The Kd of 3 from the fluorescence binding measurement is 2.53 ± 0.64 
μM, which is in the similar range as the value measured from the fluorescence anisotropy 
titration. Furthermore, we determined the binding stoichiometry of 3 with H4(1-20)FL by using 
the Job’s method (Figure 3.7). The intersecting point appears at 0.5 in the plot, suggesting that 3 
binds to H4(1-20)FL at 1:1 ratio. 
 
 
 
 
 
 
 
 
 
Figure 3.6. Impact of 3 on the fluorescence spectra of H4(1-20)FL. a. Fluorescence 
emission spectra of H4(1-20)FL (0.2 μM) at different concentrations of 3 (0 ~ 28.2 μM). 
Excitation wavelength was 498 nm. Fluorescence spectrum change of NHS-fluorescein (0.2 μM) 
upon titration with 3 was also measured as a control (Spectra not shown). b. Fluorescence 
intensity of H4(1-20)FL at 524 nm as a function of 3 concentration (after removing the inner 
filter effect). Inlet: Fluorescence intensity of NHS-fluorescein at 524 nm as a function of 3 
concentration (after correction). 
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Figure 3.7. Determination of the binding stoichiometry of 3─H4(1-20)FL complex 
by Job’s Method. The ratio of 3/H4(1-20)FL was varied while the total concentration of H4(1-
20)FL and 3 was fixed at 0.5 μM. The fluorescence intensity (524 nm) of each solution was 
measured and normalized, and plotted as a function of the molar fraction of 3. 
 
We also attempted to study 3—H4(1-20) interaction using circular dichroism (CD) 
spectra. In the spectra, H4(1-20) showed a pattern of absorption that is correspondent with 
random coil structures (Figure 3.8). Upon addition of 3, the absorption band for the random coil 
decreased, indicating that the inhibitor caused a structural change to H4 peptide. However, upon 
continuous addition of 3, a red precipitate occurred which prevented further accurate quantitative 
analysis of H4(1-20)—inhibitor interaction. Similar results were also observed for the interaction 
between 1 and H4(1-20) (data not shown). 
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Figure 3.8. CD study of H4(1-20) association with 3. 100 μM of H4(1-20) was titrated 
with 0 μM (∆), 100  μM (♦), and 200 μM (●) of 3 in 10 mM of Tris buffer (pH 7.4). CD 
spectrum change of H4(1-20) was monitored. 
 
In enzyme inhibition, if an inhibitor targets the active site of an enzyme, its inhibition 
potency will be largely determined by the binding affinity between the inhibitor and the enzyme, 
with little interference by substrates. In our case, however, the experimental findings show that 
NS compounds target the substrate, but not the enzyme. This suggests that the potency of these 
inhibitors in blocking PRMT1 activity will be greatly affected by the nature of the substrate used 
for the assay. To investigate whether this is true, we tested PRMT1-mediated methylation on 
H4(1-11) and the inhibition by 3. Indeed, 3 inhibited the methylation of H4(1-11) with an IC50 
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(i.e., 176.5 μM) significantly higher than that of H4(1-20) methylation (i.e., 12.7 μM). These 
data indicate that the inhibition caused by the NS molecules depends on the structural sequences 
of the substrates used, and strongly validate the proposal that these inhibitors target substrate, 
instead of enzyme. On the other hand, stilbamidine inhibited the methylation of H4(1-20) and 
H4(1-11) with similar Ki, i.e., 25.6 μM and 35.0 μM, respectively. Therefore, the inhibition 
mode of stilbamidine is different from that of NS compounds. Our data, in agreement with a 
previous study,(47) support that stilbamidine targets the active site of PRMT1 to compete with 
substrates. 
By now, there is no structural information available regarding the nature of H4(1-20)—3 
interaction. The potency difference of 3 in inhibiting H4(1-20) methylation versus H4(1-11) 
methylation suggests that the inhibitor targets both the N-terminal and C-terminal residues in 
H4(1-20). The 1:1 stoichiometry of H4(1-20)—3 binding indicates that the interaction is quite 
specific. Electrostatic interaction is likely a strong factor, but other modes of interactions such as 
van der Waals and hydrogen-bonding may also play significant roles. Based on the results of 
CD, fluorescence, and absorption spectral changes, it is quite possible that the secondary 
structure of the peptide substrate is altered upon inhibitor binding. 
3.2.5. 3 inhibits the activity of histone acetyltransferase (HAT) p300. 
The finding that 3 and its analogues inhibit PRMT1 activity by targeting its substrates 
implicates that 3 may also inhibit other enzymes that utilize H4 or GAR peptides as substrate. To 
test this possibility, we measured the acetylation of H4(1-20) by p300, a well known HAT that is 
able to acetylate the N-terminal tail of H4 at multiple sites.(85) The measurement was carried out 
with 0.02 μM of p300, 10 μM of [14C]-acetyl CoA, and 10 μM of H4(1-20), at varied 
concentrations of 3 or 1. Indeed, both compounds exhibited strong inhibition of p300-mediated 
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H4 acetylation (Figure 3.9). The IC50 of 3 and 1 for p300 inhibition were determined to be 21.3 ± 
2.0 μM and 118.5 ± 6.5 μM, respectively. Notably, these IC50 values are very similar as those 
obtained for PRMT1 inhibition. These data again support our conclusion that the NS-series of 
compounds bind to H4 directly, and the binding subsequently prevents H4 from being 
recognized by the H4-modifying enzymes, such as PRMT1 and p300. Thus, the inhibition caused 
by NS-series compounds depends on the binding between the inhibitor and the substrate, 
irrespective of the enzyme targets. On the other hand, although stilbamidine is a competitive 
inhibitor in PRMT1-catalyzed methylation, it does not inhibit significantly H4 acetylation 
catalyzed by p300 (Figure 3.9d); For example, at 1 mM of stilbamidine concentration, p300 still 
retained 84% of its HAT activity. Therefore, quite likely, stilbamidine targets the active site of 
PRMT1 to compete with the H4 substrate, which is in agreement with a previous study.(47)  
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Figure 3.9. Inhibition of p300 HAT activity by 3, 1, suramin and stilbamidine. The 
fractional activity of p300 was plotted in respect to the concentration of 3 (a), 1 (b), suramin (c), 
or stilbamidine (d). The reaction buffers contained 10 μM of H4(1-20), 10 μM of 14C-Acetyl 
CoA, and 20 nM of p300. 
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3.2.6. Suramin inhibits arginine methylation.  
The NS-series of compounds have great structural similarity to suramin, a symmetrical 
polyanionic aromatic urea containing two naphthalene and six sulfonate groups (Figure 3.1). We 
tested whether suramin can inhibit PRMT1-mediated methylation. Indeed, suramin strongly 
inhibited arginine methylation on both H4(1-20) and GAR substrate R4, with IC50 of 5.3 μM and 
1011 μM, respectively (Table 3.1). As a matter of fact, the inhibition potency of suramin is even 
stronger than that of 3, the most potent inhibitor identified from our screening search. 
Furthermore, suramin also inhibited the HAT activity of p300 with an IC50 of 13.7 μM (Figure 
3.9c). Given their structural analogy and the similar properties in the inhibition of methylation 
and acetylation, suramin likely shares the same mechanism of inhibition with NS compounds; 
namely suramin also targets H4 and GAR proteins and blocks PTMs on the substrates. These 
data clearly revealed a previously unknown function of sumarin.  
3.3. Conclusion 
In conclusion, we have discovered a type of organic compounds containing naphthalene 
and sulfonyl pharmacophore components that inhibit PRMT activity in the micromolar range, 
whose inhibition mechanism is fundamentally distinct from the other PRMT inhibitors reported 
so far. The biochemical and biophysical data of representative compounds (e.g., 3, 6, 1) show 
that these inhibitors are competitive versus PRMT1 substrates (e.g., H4 and GAR peptides) and 
noncompetitive versus the methyl donor. Detailed studies illustrate that they directly target the 
peptide substrates instead of PRMT1, and the binding subsequently blocks the recognition of the 
substrates by the enzyme, which is largely responsible for the observed PRMT1 inhibition effect. 
We also show that the anti-parasitic drug suramin is also an effective arginine methylation 
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inhibitor. These NS inhibitors will be useful chemical tools for mechanistic study of arginine 
methylation and other epigenetic modifications. Further, illumination of the inhibitory 
mechanism provides a new insight for understanding the pharmacological effect of these 
structurally unique molecules in biological systems. 
 
Figure 3.10. Inhibition mechanism of NS compounds. 
3.4. Experimental 
3.4.1. Materials 
Fmoc-protected amino acids and solid phase resins were purchased from NovaBiochem. 
All the screening compounds were obtained from ChemBridge Corporation. Stilbamidine and 
allantodapsone were obtained from National Cancer Institute. Suramin was purchased from 
Acros Organics. For all the effective inhibitors discovered and tested, including compounds 1, 
3—11, suramin, and stilbamidine, their purities were confirmed by analytical C18 reverse-
phased HPLC with H2O/acetonitrile gradient elution to be ≥95%. Radioactive AdoMet and 
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acetyl-CoA were ordered from GE Healthcare and Perkin Elmer. Other chemical reagents were 
purchased from Fisher, VWR, and Sigma, etc. 
3.4.2. Peptide substrates 
Peptides were synthesized using the standard solid phase peptide synthesis (SPPS) 
protocols, purified with C-18 reversed phase HPLC, and confirmed with MALDI-MS as 
previously described.(86) The structural sequence of the NH2-terminal 20 aa peptide of histone 
H4, i.e., H4(1-20), is Ac-SGRGKGGKGLGKGGAKRHRK. The structural sequence of the NH2-
terminal 11 aa peptide of histone H4, i.e., H4(1-11), is Ac-SGRGKGGKGLG. The structural 
sequence of the GAR peptide, R4, is Ac-GGRGGFGGRGGKGGRGGFGGRGGFG. The 
underlined Rs designate for the methylation sites. The NH2-terminal tail 31 aa peptide of human 
H3, H3(1-31), was synthesized and used as a substrate in CARM1 and PRMT6 analyses. The 
structural sequence of H4(1-20)FL is Ac-SGRGKGGKGDpr(FL)GKGGAKRHRK. Dpr stands 
for 2,3-diaminopropionic acid. The structural sequence of R4FL is Ac-
GGRGGFGGRGGK(FL)GGRGGFGGRGGFG. In both cases, the fluorescein (FL) is attached 
through the side chain amino group. 
3.4.3. Protein expression and purification 
His6x-tagged PRMT1 was expressed from pET28b vector. GST-PRMT1 is expressed 
from pGEX-4T1 vector. His6x-tagged PRMT3 was expressed from the pReceiver vector. GST-
mCARM1 was expressed from the pGEX-4T1 vector. His6x-tagged PRMT6 was expressed from 
the pET28a vector. All the proteins were expressed in E. coli BL21(DE3). All the His6x-tagged 
proteins were purified on Ni-NTA beads, and the GST-tagged proteins were purified on 
glutathione agarose beads. Protein concentrations were determined using Bradford assay.  
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3.4.4. Virtual screening 
The virtual screening was conducted on a 40-node Linux cluster at Georgia State 
University using the same protocol as described before.(87, 88) The 2D structures of 
ChemBridge database (about 0.4 million compounds) were first converted into 3D structures by 
using the CONCORD program.(81) Hydrogen atoms were then added to the 3D ligand structures 
and all atoms were assigned with AM1-BCC partial charges(89-91) by the QuACPAC 1.1 
software.(92) These structures were firstly examined based on drug-like property by the FILTER 
2.0.1 software.(93) Before docking-based virtual screening, the PRMT1 structure (PDB entry: 
1OR8) was added with hydrogen atoms and assigned with Kollman-all charges by the SYBYL 
7.1 program.(94) Residues including Arg 3, Arg 9, Arg 15, Ile 44, His 45, Met 48, Leu 49, Arg 
54, Thr 55, Asp 76, Val 77, Gly 78, Ser 79, Gly 80, Thr 81, Gly 82, Ile 83, Leu 84, Ile 99, Glu 
100, Cys 101, Ser 102, Ile 104, Gly 126, Lys 127, Val 128, Glu 129, Ser 143, Glu 144, Met 155 
and Thr 158, were defined as the active site to construct a grid for the structure-based virtual 
screening. The position and conformation of each compound were optimized firstly by the 
anchor fragment orientation and then by the torsion minimization method implemented in the 
DOCK 6 program.(82) Fifty conformations and a maximum of 100 anchor orientations for each 
compound were generated, and all of the docked conformations were energy minimized by 100 
iterations following procedures as described in literature.(82) The docked molecules were ranked 
based on the sum of the van der Waals and electrostatic energies implemented in the DOCK 6 
program to obtain the top 1000 compounds. After collecting the top hits, the consensus scoring 
evaluation(95), including ChemScore,(96, 97) PLP,(98) ScreenScore,(99) ChemGauss and 
ShapeGauss(100) implemented in the FRED 2.2.3 program, was processed,(93) as well as 
hydrogen bond and hydrophobic profiles by the IDEA 8.8 software.(101) As the final step, a 
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manual binding orientation and conformational examination was performed to harvest the final 
fifty hits for biochemical evaluation. 
3.4.5. Radioactive methylation assay 
The inhibitory activities of small molecule compounds were tested using carbon-14 
labeled radioactive methylation assays. The assays were carried out in 0.6-mL plastic tubes at 
30°C in a reaction volume of 30 μL. The reaction buffer contained 50 mM HEPES (pH = 8.0), 
0.5 mM DTT, 1 mM EDTA, and 50 mM NaCl. In a typical procedure, 2 μM of peptide substrate, 
5 μM of [14C]-AdoMet and varied concentrations of an inhibitor were preincubated in the 
reaction buffer for 5 min prior to the initiation by the addition of PRMT1 (0.1 μM final). After 
incubating for an appropriate period of time, the reaction was quenched by spreading the reaction 
mixture onto P81 filter paper discs (Whatman). The paper disc was washed with 1 liter of 50 mM 
NaHCO3 and dried in air for 2 hours. The amount of methylated products was quantified by 
liquid scintillation. IC50 value is the concentration of inhibitor at which half of the maximal 
activity is reached. The Ki for stilbamidine was calculated from IC50 by using the equation: 
 . Km was obtained by measuring the initial velocity of reaction at different 
concentrations of a particular substrate and fitting the kinetic data with Michaelis-Menton 
equation. The inhibition patterns of 3 and 6 were determined by measuring initial velocities of 
PRMT1 at a range of varied concentrations of one substrate, a fixed concentration of the other 
substrate, and selected concentrations of the inhibitors. The data were displayed in double 
reciprocal formats and fitted to competitive or noncompetitive kinetic equations.(102) 
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3.4.6. Inhibition of p300 catalysis  
Recombinant p300 HAT domain (1287-1666) was a gift from Dr. Philip Cole at Johns 
Hopkins University and its expression was described in an earlier report.(103) Enzymatic 
activity of p300 and its inhibition by 3 and other compounds were measured by radioactive 
acetylation assays. A reaction mixture of 10 μM of H4(1-20), 10 μM of [14C]-acetyl CoA, 20 nM 
of p300, and increasing concentrations of the inhibitors were incubated in the reaction buffer (50 
mM HEPES (pH 8.0), 50 mM NaCl, 0.5 mM DTT, 1 mM EDTA) at 30 ºC for 10 min, and the 
reaction was quenched by loading the mixture onto p81 filter paper. The radioactive products 
were quantified by liquid scintillation and the fractional activity of p300 was plotted in respect to 
the concentration of individual inhibitors.  
3.4.7. Fluorescent binding assay.  
Fluorescence intensity and anisotropy of fluorescein-labeled peptides were measured on a 
Fluoromax-4 spectrofluorometer (Horiba Jobin Yvon). The buffer was the same as that for the 
radioactive assay. The excitation wavelength and emission wavelength were selected at 498 nm 
and 524 nm, respectively. The competitive binding of small molecule compounds to PRMT1-
substrate solution was measured using the fluorescence anisotropy mode in similar manners as 
described previously.(83) Typically, 0.2 μM of H4(1-20)FL and 2 μM of PRMT1 were mixed, 
and increasing concentrations of an inhibitor were added until the fluorescence anisotropy 
signals leveled off. The anisotropy values at 524 nm from several scans were plotted as a 
function of inhibitor concentration. Data were fitted with competitive binding model using 
DynaFit program to calculate the Ki value.(84, 104) Also, fluorescence intensity changes of 
H4(1-20)FL at different concentrations of 3 were measured in order to detect their interaction. 
0.2 μM of H4(1-20)FL at 30ºC was titrated with increasing concentrations of 3 (0 ~ 28.2 μM). 
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NHS-fluorescein was used as a control. The fluorescence intensities of both H4(1-20)FL and 
NHS-fluorescein were corrected to remove the inner filter effect that was caused by 3 absorption, 
and the data were plotted as a function of the concentration of 3. The Job’s Method was applied 
to determine the binding stoichiometry of 3 with H4(1-20)FL. A series of solutions with a fixed 
total amount (0.225 nmol) but varied ratios (0~9) of 3 and H4(1-20)FL in the same reaction 
buffer were prepared. The fluorescence intensity of each sample at 524 nm was measured, which 
is related to the amount of binding complex. The fluorescence intensity was divided by the molar 
fraction of H4(1-20)FL, and then plotted as a function of the molar fraction of 3.  
3.4.8. UV-Vis spectroscopy of 3 upon titration with H4(1-20) or PRMT1. 
The UV-Vis spectra of compound 3 (40 μM in the same reaction buffer) were acquired 
on a Shimadzu UV-1700 spectrophotometer, in the presence of different concentrations of H4-20 
or PRMT1. 
3.4.9. CD measurement.  
CD spectral changes of H4(1-20) upon the addition of different concentrations of 3 were 
measured on a Jasco J-810 spectropolarimeter. 100 μM H4(1-20) was titrated with 0  μM, 100  
μM, and 200 μM of 3 in 10 mM Tris buffer (pH 7.4) in a 400 μl CD cuvette. CD spectrum of 
each equilibrated sample was scanned (100 nm/min) with an accumulation of 3 times. 
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CHAPTER 4 
A TRANSIENT KINETIC ANALYSIS OF PRMT1 CATALYSIS 
(This work is mainly based on the published paper, Biochemistry. 50 (2011) 7033-44. In this 
project, the author is obliged to Dr. Nan Xie and Miyeong Jin for their contributions to prepare 
the peptide compounds, and Dr. Mary R. Stahley and Dr. James T. Stivers for their assistance in 
stopped-flow fluorometer analysis.)  
4.1. Introduction 
Arginine methylation of the core histones is catalyzed by protein arginine 
methyltransferases (PRMTs), which transfer the methyl group from S-adenosyl-L-methionine 
(SAM) to the guanidino group of specific arginine residues. Thus far, about nine PRMT 
members have been identified at the proteomic level in mammalian cells and these have been 
grouped into two major types (type I and type II) according to their product specificity (18-20). 
Type I enzymes (PRMT1, 2, 3, 4, 6, and 8) catalyze the transfer of the methyl group from SAM 
to one guanidino nitrogen atom of arginine residue to produce ω-NG monomethylarginines 
(MMA, L-NMMA) and ω-NG, NG-asymmetric dimethylarginines (ADMA) [for a review, see a 
ref. (21)]. Type II enzymes (e.g., PRMT5) catalyze the formation of MMA and ω-NG, N’G-
symmetric dimethylarginines (SDMA) (24-27). As a result of the methyl transfer, SAM is 
converted to the product S-adenosyl-L-homocysteine (SAH). PRMTs can exhibit quite high 
substrate specificity which is correlated with their different specific functions. For instance, 
CARM1 (PRMT4) methylates H3R2, H3R17 and H3R26 (65, 105), while PRMT1 and PRMT5 
specifically methylate H4R3 and H3R8 (40, 76). The methylation at distinct sites can affect the 
status of gene expression differently. For instance, asymmetric dimethylation at H3R17 and 
H4R3 stimulates gene activation, whereas symmetric dimethylation at H4R3 is associated with 
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gene repression (40, 106, 107). In general, PRMT-catalyzed arginine methylation is essential for 
many biological processes including gene transcriptional regulation (40, 56, 76, 105, 106, 108, 
109), signal transduction (110-113), RNA transport (24, 114), RNA splicing (57, 115), DNA 
repair, and embryonic development and cellular differentiation (58, 116, 117). 
Scheme 4.1. PRMT1-catalyzed arginine methylation. 
PRMT1
AdoMet SAH
N
H
O
NH
H
NH2
H2N
N
H
O
NH
H
NH
H2N
H3C
N
H
O
NH
H
N
H2N
H3C
CH3AdoMet SAH
PRMT1
 
Several studies of the kinetic mechanism of arginine methylation have been recently 
reported. One steady-state kinetic analysis suggested that PRMT1 utilizes a rapid equilibrium 
random mechanism (RER) for methyl transfer with the formation of dead-end EAP and EBQ 
complexes (33). In another study, PRMT6 was shown to follow an ordered sequential 
mechanism in which SAM binds to the enzyme first and the methylated product is the first to 
dissociate (34). The slight difference in these two studies may suggest that kinetics of arginine 
methylation can vary slightly among the individual isoforms. Nevertheless, both studies support 
a sequential kinetic mechanism in which a ternary complex is formed prior to the methyl transfer 
step. 
Many important questions about the PRMT-catalyzed arginine methylation reaction 
remain to be answered. For instance, it is not known whether the chemical step or a protein 
conformational change in the ES complex is rate-limiting for catalysis. Such a molecular level 
64 
 
 
understanding of how substrate recognition is coupled to catalysis will be of great significance to 
evaluate the function of PRMT activity in different physiological contexts. To address these 
mechanistic questions, transient kinetic analyses of arginine methylation are highly desirable. 
Unfortunately, such studies are greatly limited by lack of assay tools appropriate for fast 
measurement of substrate binding and methylation on rapid time-scales. In particular, routine 
radioisotope-labeled methyl transfer assays do not provide information about conformational 
events along the reaction coordinate. Recently, we reported fluorescently labeled peptide 
substrates that could be useful in studies of substrate binding and methylation (118). Here we 
report that such substrates serve as excellent tools to dissect the transient kinetic events during 
PRMT1 catalysis. By using fluorophore-labeled H4 substrates in combination with stopped flow 
measurements, we have determined the microscopic rate constants for the key binding and 
methylation steps during PRMT1 catalysis. This study provides kinetic evidence that substrate 
recognition induces a conformational transition of the active site of PRMT1, and strongly 
indicates that the methyl transfer step is overall rate-limiting for arginine methylation. In 
addition, we find that binding of the cofactor SAM/SAH modulates the interaction between 
PRMT1 and the peptide substrate.  
4.2. Results and Discussion 
4.2.1. Oligomerization of PRMT1 stimulates its activity. 
To understand the process of methylation, we first checked the oligomeric state of 
PRMT1, as this enzyme has been reported to function as a homo-dimer or oligomers (30). 
Different concentrations of PRMT1 were incubated with glutaraldehyde (0.025%, v/v) for 5 min. 
0.1% Triton X-100 was added to eliminate the nonspecific interactions. The mixtures were 
resolved using 8% SDS-PAGE and probed with anti-PRMT1 antibody. It is clear that as the 
65 
 
 
protein concentration increases, the degree of oligomerization also increases until it reaches a 
plateau (Figure 4.1a and b). We further tested if there is a correlation between the activity of 
PRMT1 and its concentration. As Figures 4.1c and 4.1d reveal, the slope of a plot of the apparent 
Vmax divided by PRMT1 concentration (i.e. the apparent kcat) is not constant as the PRMT1 
concentration changes. In other words, the turnover rate per PRMT1 monomer becomes higher 
as its concentration increases, and then plateaus when it rises above ~0.5 μM. Together, these 
data suggest that PRMT1 oligomerization is dependent on concentration in the range of 0 to 0.5 
μM, and that the final PRMT1 oligomeric complex is the most active form. 
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Figure 4.1. Concentration dependence of PRMT1 oligomerization and catalytic 
activity.  (a) Western blot analysis of PRMT1 oligomerization. Different concentrations of 
PRMT1 (0.012 μM ⎯ 3.13 μM) were prepared in presence of 0.1% Triton X-100 and incubated 
with 0.025% (v/v) glutaraldehyde for 5 min. The crosslinked proteins were resolved on 8% SDS-
PAGE followed by western blot detection (primary antibody: anti-PRMT1 rabbit polyclonal IgG; 
secondary antibody: goat anti-rabbit IgG-HRP). Lane 1 to 9: marker, 0.012 μM, 0.024 μM, 0.05 
μM, 0.10 μM, 0.20 μM, 0.39 μM, 0.78 μM, and 1.56 μM of PRMT1. (b) Concentration-
dependent oligomerization of PRMT1. The western blot densitometry was analyzed by Quantity 
One software, and the fractions of PRMT1 monomer, dimer and oligomer were plotted as a 
function of PRMT1 concentration. (c) Maximum velocity as a function of PRMT1 concentration. 
0 ~ 3.13 μM of PRMT1 was added to the reaction buffer containing 18.75 μM of [14C]-SAM and 
18.75 μM of H4-20. The total protein concentration for each reaction was controlled at 3.13 μM 
by including BSA as a carrier protein, eliminating the effect of nonspecific interaction. Each 
reaction was quenched at less than 20% yield. (d) Apparent kcat as a function of PRMT1 
concentration. The data were deduced from (c) by dividing the maximum velocity with the 
corresponding enzyme concentration.  
 
4.2.2. H4 peptide synthesis and steady-state kinetic characterization. 
To create fluorescent probes for study of the PRMT-substrate interaction and 
methylation, we synthesized several peptides containing N-terminal 20 amino acids of histone 
H4, with 0, 1 or 2 methyl groups on Arg-3 and a fluorescein group on Dpr-10 (2,3-
diaminopropionic acid residue, substituting for Leu-10) (Table 4.1). H4FL and H4FLme1 are 
substrates of PRMT1, and H4FLme2 is a product of PRMT1 catalysis. In this design, the 
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fluorescein group is placed at an optimized position relative to the methylation site, such that the 
label does not affect substrate methylation but might still be sensitive to the local change in 
microenvironment induced by ligand binding. These fluorescent peptides were synthesized with 
the Fmoc-based solid phase peptide chemistry strategy, purified by HPLC, and analyzed by 
MALDI-MS. 
Table 4.1. Sequences of H4 peptides.  
Dpr: 2,3-diaminopropionic acid residue; FL: fluorescein group; me: methyl group. 
Peptide name Sequence 
H4(1-20) Ac-SGRGKGGKGLGKGGAKRHRK 
H4FL Ac-SGRGKGGKGDpr(FL)GKGGAKRHRK 
H4FLme1 Ac-SGRme1GKGGKGDpr(FL)GKGGAKRHRK 
H4FLme2 Ac-SGRme2GKGGKGDpr(FL)GKGGAKRHRK 
 
After the peptide synthesis and characterization, we measured the steady-state kinetic 
parameters of PRMT1 catalysis with these substrates. [14C]-SAM was used as the methyl donor 
for the methyltransferase reactions, enabling us to quantify the methylated products by liquid 
scintillation counting. In the steady-state initial rate assays, one substrate concentration was 
varied and the other substrate was fixed in large excess (at least five-fold higher than its Km) to 
ensure pseudo first-order reaction conditions. Each reaction was quenched at an appropriate time 
to ensure that substrate conversion was less than 20%. As shown in Table 4.2, the Km and kcat 
values of peptide for H4(1-20) and H4FL vary by less than three-fold, indicating that fluorophore 
does not significantly affect substrate methylation by PRMT1. Also, in a competitive 
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fluorescence anisotropy assay, H4(1-20) was found to completely reverse the binding of H4FL to 
PRMT1 (Figure 4.3), indicating that the fluorescein-labeled peptide has the same binding mode 
to the enzyme as the label-free peptide. In addition, these synthesized peptide substrates exhibit 
comparable kinetic parameters as histone H4 protein, demonstrating that they are good 
representatives of H4 protein. The kcat/Km values for un-methylated H4FL and mono-methylated 
H4FLme1 are 0.86 ± 0.09 μM-1 min-1 and 1.6 ± 0.29 μM-1 min-1, respectively, suggesting that 
PRMT1 has little preference for arginine-mono-methylated H4 peptide. The binding affinity 
between the fluorescein-labeled peptides and PRMT1 was measured by fluorescence anisotropy 
titrations (118), taking advantage of the fact that the large enzyme-peptide complex has a larger 
correlation time and higher anisotropy than the peptide ligand (Figure 4.2). The Kd values for the 
binding of H4FL, H4FLme1 and H4FLme2 to PRMT1 apoenzyme (0.47 ± 0.06 μM, 0.74 ± 0.13 
μM, and 0.44 ± 0.09 μM, respectively) are very similar, suggesting that PRMT1 does not 
appreciably distinguish among the three peptide forms, although the Km of H4FLme1 (0.17 ± 
0.03 μM) is somewhat lower than the other two peptides. It is possible that binding of cofactor 
SAM to PRMT1 alters its interaction with the peptide substrate.  
Table 4.2. Steady-state kinetic characterization of PRMT1 binding and catalysis. 
The radioactive methylation assays were carried out at 30°C and pH 8.0. PRMT1 Concentration 
was typically 0.01 μM in the catalytic experiments. Kd values were detected in fluorescence 
anisotropy titration using constant fluorescent peptide (0.2 μM) and increasing concentration of 
PRMT1.  
Substrates Km, μM kcat, min-1 kcat/Km, μM-1 min-1 Kd, μM 
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H4 protein 1.69 ± 0.39 0.50 ± 0.03 0.30 ± 0.07 - 
H4(1-20) 0.64 ± 0.04 0.81 ± 0.01 1.27 ± 0.08 - 
H4FL 0.50 ± 0.05 0.43 ± 0.01 0.86 ± 0.09 0.47 ± 0.06 
H4FLme1 0.17 ± 0.03 0.27 ± 0.01 1.60 ± 0.29 0.74 ± 0.13 
H4FLme2 - - - 0.44 ± 0.09 
SAM (for H4FL 
methylation) 
3.10 ± 0.46 0.48 ± 0.02 0.15 ± 0.02 - 
SAM (for H4FLme1 
methylation) 
1.59 ± 0.37 0.33 ± 0.02 0.21 ± 0.05 - 
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Figure 4.2. Fluorescence anisotropy titration of fluorescent peptides with PRMT1. 
0.2 μM of H4FL (a), H4FLme1 (b) or H4FLme2 (c) was titrated with increasing concentration of 
PRMT1 at 30ºC in the reaction buffer mentioned above, and the anisotropy change due to large 
ES complex formation was recorded, with 498 nm excitation and 524 nm emission. Data were fit 
to eq 1 to calculate the Kd values.  
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Figure 4.3. Fluorescence anisotropy change of H4FL binding to PRMT1 followed by 
H4(1-20) competitive titration. Data were collected on a Fluoro-Max 4 fluorimeter (Horiba 
Jobin Yvon) with the excitation and emission at 498 nm and 524 nm respectively. 0.2 μM of 
H4FL (1) and 2 μM of PRMT1 (2) were added into the reaction buffer sequentially to show the 
anisotropy increase. Then increasing concentration of unlabeled H4(1-20) were titrated into the 
H4FL-PRMT1 mixture to show the anisotropy decay due to the competitive binding of H4(1-20) 
and H4FL to PRMT1.  
4.2.3. Measurement of the binding rate constants of the H4 peptides with PRMT1. 
Our fluorescein-labeled H4 peptide showed an appreciable fluorescence decrease when 
mixed with excess amounts of PRMT1, which was reversed by adding increasing concentrations 
of unlabeled H4(1-20) (Figure 4.4). This indicates a change in the environment for the 
fluorescein group upon substrate-enzyme interaction, and provides a signal to measure the 
association rate constant of the fluorescent peptide with PRMT1 using stopped flow 
fluorescence. In the transient kinetics experiments, the fluorescent peptide was rapidly mixed 
with increasing concentrations of PRMT1 (in large excess over the substrate), and the time-
dependent fluorescence signal change was monitored to obtain the observed rate constants (kobs). 
Typical time courses for H4FL, H4FLme1 and H4FLme2 are shown in Figures 4.5a, 4.5b, and 
4.5c. Each averaged data curve was fitted well to a single-exponential function, suggesting no 
more than a simple single-step process. The kobs data were calculated and plotted against PRMT1 
concentration (Figure 4.5d and Figure 4.6). The association rate constant (kon) was obtained from 
the slope of the plot of kobs against PRMT1 concentration to be 40 ± 1 μM-1s-1 for H4FL, 23 ± 1 
μM-1s-1 for H4FLme1, and 26 ± 1 μM-1s-1 for H4FLme2. 
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Figure 4.4. Fluorescence change of H4FLme1 association followed by H4(1-20) 
competitive titration. Data were collected on a Fluoro-Max 4 fluorimeter (Horiba Jobin Yvon) 
with the excitation and emission at 498 nm and 524 nm respectively. 2 μM of PRMT1 and 100 
μM of SAH were added into the reaction buffer containing 0.4 μM of H4FLme1 sequentially to 
show the fluorescence decrease. Then increasing concentration of unlabeled H4(1-20) were 
titrated into the bi-subtrate-enzyme mixture to show the fluorescence recovery due to 
competitive binding of H4(1-20) and H4FLme1 to PRMT1. (1) H4FLme1 (0.4 μM); (2) 
H4FLme1 (0.4 μM) + PRMT1 (2 μM); (3) H4FLme1 (0.4 μM) + PRMT1 (2 μM) + SAH (100 
μM). 
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Figure 4.5. Stopped-flow measurements of peptide association with PRMT1. Panel 
(a), (b), and (c) show the fluorescence change of H4FL, H4FLme1, and H4FLme2 (0.4 μM) 
upon mixing with PRMT1 (4 μM) at 30 ºC in the reaction buffer, respectively. Excitation 
wavelength was selected at 495 nm and emission ≥510 nm was detected. Each sample was 
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injected 4 to 6 times. The black dots show the averaged data points, and the curves are fit with eq 
2. Panel (d) shows the observed association rate constant of H4FLme1 plotted against the 
concentration of PRMT1. The data were fit to linear eq 4.  
 
 
 
 
 
Figure 4.6. Plot of kobs versus protein concentration obtained from stopped-flow 
fluorescence measurements. Panel (a) and (b) show the linearity between the observed 
association rate constant and PRMT1 concentration for H4FL and H4FLme2, respectively. 0.4 
μM fluorescent peptide was mixed with increasing concentration of PRMT1 (2, 4 and 6 μM) at 
30 ºC in the reaction buffer. Excitation was 495 nm and emission was ≥510 nm. Each sample 
was injected 4~6 times.  
 
4.2.4. Measurement of dissociation rate constants of peptides from PRMT1.  
We next measured dissociation rate constants (koff) of H4FL, H4FLme1, H4FLme2 from 
PRMT1. A trapping experiment was designed as previously described (119). In this 
measurement, one solution containing 0.4 μM fluorescent ligand and 2 μM PRMT1 was rapidly 
(a)  (b) 
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mixed with the other solution containing a large excess of unlabeled H4 peptide, i.e., 50 μM of 
H4(1-20). Following mixing, the fluorescent ligand dissociated from the PRMT1 complex, and 
the free PRMT1 was trapped with excess H4(1-20). The single-exponential time course reflects 
this dissociation process, with the expected recovery of fluorescence of the labeled peptide as it 
is released to bulk solution (Figure 4.7). The dissociation rate constants obtained from these 
measurements are 333 ± 9 s-1 for H4FL, 292 ± 3 s-1 for H4FLme1, and 319 ± 6 s-1 for H4FLme2. 
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Figure 4.7. Stopped-flow measurements of peptide dissociation from PRMT1. 0.4 
μM fluorescent peptide was premixed with 2 μM PRMT1 in the reaction buffer. The solution 
was then rapidly mixed with 50 μM H4(1-20) on stopped-flow instrument at 30 ºC. Each sample 
was injected 4 to 6 times. The black dots show the averaged data points, and the curves are fit 
with eq 2. (a), (b), and (c) show the dissociation time courses of H4FL, H4FLme1, and 
H4FLme2 from PRMT1, respectively. 
4.2.5. Effect of SAH on enzyme binding and dissociation of H4FLme1.  
We also examined how the cofactor analog SAH affects the association and dissociation 
of the fluorescent substrate H4FLme1 with PRMT1. For the binding experiment, 100 μM of 
SAH was preincubated with PRMT1 (2, 4, and 6 μM) prior to rapid mixing with H4FLme1. The 
time course for PRMT1-SAH binding with H4FLme1 was monitored with stopped-flow 
fluorescence (Figure 4.8a). It is noted that the magnitude of the fluorescence change of 
H4FLme1 upon association with PRMT1-SAH is 2-fold larger than its binding with apo PRMT1 
under the same condition (Figure 4.5b), and the association rate constant is two-fold higher 
(Table 4.3), indicating that SAH modulates the microenvironment of the fluorophore in the ES 
complex. More importantly, the time course data can only be fitted to a double exponential 
function, rather than a single exponential function as observed above, suggesting that the binding 
is not a single-step process and that minimally two steps are involved (Scheme 4.2b). The double 
exponential fitting produces two sets of kobs, one for a fast phase and the other for a slow phase 
(phase 1 and phase 2 in Figure 5a, 5b). The rate constant values can be further fit to a two-step 
binding model (eq 5) (120). The first-step binding rate constant k1 was determined from the slope 
of the fast phase as 48 ± 1 μM-1s-1. The plateau of the slow phase (36 ± 2 s-1) corresponds to the 
sum of k2 and k-2, and the difference on the ordinate axis between this plateau and the intercept of 
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the fast phase yields 117 ± 3 s-1 for k-1. Also, we measured the dissociation progression course for 
H4FLme1 from PRMT1 in the presence of 100 μM SAH (Figure 5c). Similar to the dissociation 
experiment for the H4FLme1⎯PRMT1 complex, excess H4(1-20) was used as the trapping 
ligand. Again, the dissociation time course could not be fitted to a single exponential function, 
confirming that the binding of H4FLme1 with PRMT1-SAH is not a single-step process. The 
two rate constants obtained from the double exponential fit (109 ± 1 s-1 and 19 ± 0.2 s-1) 
correspond to the two reverse rate constants in the two-step binding model (k-1 and k-2 in Scheme 
4.2b). Of note, the k-1 value from the trapping experiment is very close to that obtained from the 
binding experiment, supporting the validity of the two-step model. Combining the kinetic data 
for binding and dissociation, all the four rate constants of Scheme 4.2b were calculated. The koff 
for H4FLme1 dissociation from PRMT1-SAH complex is about three-fold lower than that of 
apo-PRMT1 (Table 4.3). In addition, the presence of 100 μM SAH or SAM was found to have a 
similar effect on the dissociation of H4FLme2 from the PRMT1-cofactor complex as described 
above (Figure 4.8d and Figure 4.9), lowering its koff to 204 ± 3 s-1 or 163 ± 3 s-1, respectively. 
The kinetic difference between H4 peptide binding to holo-PRMT1 and to apo-PRMT1 suggests 
that the presence of the cofactor modulates the PRMT1-substrate interaction. 
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Figure 4.8. Effect of SAH on the binding and dissociation of H4 substrate. Panel (a) 
shows the fluorescence change of H4FLme1 (0.4 μM) upon mixing with a solution containing 4 
μM PRMT1 and 100 μM SAH at 30 ºC in the reaction buffer. The data are fit with a double-
exponential function (eq 3). The observed rate constants for phase 1 and phase 2 are plotted 
against the concentration of PRMT1 (or PRMT1-SAH complex), and the data are fit to eq 5 to 
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get the four rate constants for the two phases, as shown in panel (b). Panel (c) and (d) show the 
dissociation time course of H4FLme1 and H4FLme2 from PRMT1-SAH complex, respectively. 
0.4 μM fluorescent peptide was premixed with 2 μM PRMT1 and 100 μM SAH in the reaction 
buffer. The solution was then rapidly mixed with 50 μM H4(1-20) on stopped-flow instrument. 
The data are fit to eq 3.  
 
 
 
 
 
 
 
Figure 4.9. Stopped-flow measurement of H4FLme2 dissociation from PRMT1-
SAM complex. 0.4 μM fluorescent peptide was premixed with 2 μM PRMT1 in presence of 100 
μM SAM in the reaction buffer. The solution was then rapidly mixed with 50 μM H4(1-20) on 
stopped-flow instrument at 30ºC. The sample was injected 4~6 times. The black dots show the 
averaged data points, and the curve is fit with a double exponential equation (eq 3). 
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Scheme 4.2. Two different kinetic models of substrate association with PRMT1 
apoenzyme and holoenzyme. (a) Single-step binding model between H4FLme1 and PRMT1. 
(b) Two-step binding model between H4FLme1 and PRMT1-SAH complex. E: open-state 
PRMT1. E’: closed-state PRMT1. 
E  SAH  H4me1 E'  SAH  H4me1E  SAH    +    H4me1
k1
k-1
k2
k-2
E  H4me1E    +   H4me1
k1
k-1
(a)
(b)
 
4.2.6. Progression of arginine methylation probed by stopped-flow fluorescence.  
Having determined the binding and dissociation rate constants of H4 substrates and 
products, we then investigated possible fluorescence signal changes that reflect PRMT1-
mediated methylation. Toward this end, we measured the fluorescence changes of H4FL and 
H4FLme1 over the entire methylation reaction course (Figure 4.10a and 4.10b). In the stopped-
flow experiments, a solution containing 2 μM PRMT1 and 100 μM SAM was mixed with a 
solution containing 0.4 μM fluorophore-labeled substrate to initiate the methylation. Such single-
turnover conditions increase the chance of identifying active enzyme intermediates. Interestingly, 
a biphasic time course was observed. The fluorescence signal for the first phase decreased (phase 
I), and then gradually increased until a plateau was reached (phase II). A double exponential 
function was applied to determine the rate constants for the two phases (0.14 ± 0.01 s-1 and 0.022 
± 0.001 s-1 for the methylation of H4FL, and 7.2 ± 0.2 s-1 and 0.034 ± 0.001 s-1 for the 
methylation of H4FLme1). The second phase, i.e. the slower phase, likely reflects the methyl 
transfer step because the rate constants are in the same range as the kcat values measured from the 
steady-state experiments (0.43 ± 0.01 min-1, 0.27 ± 0.01 min-1, Table 4.2). Also, product release 
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cannot contribute to the slow phase given that the dissociation rate constants of H4FLme1 and 
H4FLme2 (Table 4.3) are several thousand-fold larger than the rate constants for the slow phase. 
On the other hand, the fast phase observed in the time course is of great interest. It does not 
relate to the substrate binding, because the observed first-order rate constants for binding of the 
substrate (e.g., 248 ± 3 s-1 for H4FLme1 at 2 μM of PRMT1 in presence of the cofactor) are 
significantly greater than the rate constants for phase I in the methylation experiments (i.e., 0.14 
± 0.01 s-1, 7.2 ± 0.2 s-1). Indeed, if a closer look is taken at the very early part of the first phase 
(Figure 4.10a and 4.10b, inlets), an even faster phase can be discerned, which likely corresponds 
to the substrate binding step. Therefore, the first phase in the methylation course reveals a new 
step existing after the ternary complex formation, and prior to the methyl transfer step. Most 
likely, the newly discovered step corresponds to an enzyme isomerization step towards a 
catalytically active form in preparation for methyl transfer. 
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Figure 4.10. Time course of PRMT1 catalysis probed by stopped-flow fluorescence. 
(a) H4FL was used to probe the progression of two methyl transfer; and (b) H4FLme1 was used 
to detect the progression of the second methyl transfer. In both measurements, 0.4 μM 
fluorescent peptide was mixed with a solution containing 2 μM PRMT1 and 100 μM SAM at 
30ºC in the reaction buffer. Each reaction was performed 4 to 6 times, and the black dots show 
the averaged data points. The data are fit with eq 3. Inlet graphs magnify the data points at the 
very early stage of the reaction. 
Table 4.3. Summary of rate constant data obtained from stopped-flow fluorescence 
measurements. * indicates the rate constant for the fast phase (phase 1) calculated from double-
exponential fitting. 
 
Rate 
constants 
    
Peptides 
Association 
with 
PRMT1 
(μM-1s-1) 
Association 
with PRMT1-
SAH 
(μM-1s-1)* 
Dissociation 
from 
PRMT1 
(s-1) 
Dissociation 
from PRMT1-
SAH 
(s-1) 
Dissociation 
from PRMT1-
SAM 
(s-1) 
First phase in 
the course of 
methylation 
(s-1) 
Second 
phase in the 
course of 
methylation 
(s-1) 
H4FL 40 ± 1 - 333 ± 9 - - 0.14 ± 0.01 
0.022 ± 
0.001 
H4FLme1 23 ± 1 48± 1 292 ± 3 109 ± 1* - 7.2 ± 0.2 
0.034 ± 
0.001 
H4FLme2 26 ± 1 - 319 ± 6 204 ± 3 s* 163 ± 3* - - 
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Scheme 4.3. Proposed minimal kinetic model of PRMT1 catalysis. (a) first 
methylation and (b) second methylation of H4. The chemical step is rate-limiting. E: open-state 
PRMT1. E’: closed-state PRMT1. 
E  SAM E  SAM  H4
H4
E'  SAM  H4 E  SAH  H4me1
0.062 ± 0.003s-10.14 ± 0.01s-1
E'  SAH  H4me1
19 ± 0.2 s-1
17 ± 2 s-1
E  SAM  H4me1 E'  SAM  H4me1 E  SAH  H4me2
0.034 ± 0.001s-17.2 ± 0.2 s-1
E'  SAH  H4me2
34 ± 0.5 s-1
E  SAM
H4me1
E  SAH + H4me2
E  SAH + H4me1
204 ± 3 s-1
109 ± 1 s-1
(a)
(b)
 
4.3. Conclusion 
Our stopped-flow fluorescence data provide a detailed view of arginine methylation 
catalyzed by PRMT1. Under this scheme, the methyl transfer step is the major rate-limiting step 
which proceeds much more slowly than substrate association/dissociation. Binding of cofactor 
SAM/SAH appreciably affects the interaction between H4 peptide and the enzyme, probably due 
to a conformational change upon enzyme-cofactor complex formation. Importantly, the transient 
kinetics data reveal a conformational transition step following the substrate binding and prior to 
the chemical step. This protein isomerization likely reorganizes the active site of PRMT1 from 
an open state to a closed state, activating the side-chain terminal nitrogen of H4R3 and/or the 
reactive methyl group of SAM to facilitate the methyl transfer. Further structural studies will be 
essential to validate this kinetic proposition. 
4.4. Experimental 
4.4.1. Design and synthesis of modified H4 peptides 
The amino-terminal peptide of histone H4 containing the first 20 amino acid residues 
with different methylation patterns and a fluorescein group were synthesized using Fmoc [N-(9-
fluorenyl) methoxycarbonyl]-based solid phase peptide synthesis (SPPS) protocol on a PS3 
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peptide synthesizer (Protein Technology. Tucson, AZ) as described previously (86). Each amino 
acid was coupled to the solid phase with 4 equivalents of amino acid/HCTU [O-(1H-6-
Chlorobenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate] (Novabiochem, 
Darmstadt, Germany). The Fmoc group was deprotected with 20% v/v piperidine/DMF, and the 
N-terminal amino acid was acetylated with acetic anhydride. The peptide was cleaved from the 
Wang resin by a cleavage solution consisting of 95% trifluoroacetic acid (TFA), 2.5% H2O and 
2.5% triisopropylsilane. It was then precipitated in cold ether and pelleted by centrifuge. Crude 
peptides were collected and purified using a Varian Prostar instrument equipped with a C18 
Reversed-phase High Performance Liquid Chromatography (RP-HPLC) column, where 0.05% 
TFA-containing water and 0.05% TFA-containing acetonitrile were two mobile phases used in 
gradient purification. The purity and identity of peptides were confirmed by MALDI-MS. For 
the peptides linked to a fluorescein group, their concentrations were calibrated according to the 
absorption of fluorescein at 492 nm. 
4.4.2. Expression and purification of PRMT1 
Recombinant His-tagged rat PRMT1 was expressed in E. coli and purified with Ni-
charged His6x-tag binding resin as reported previously (121). Briefly, the PRMT1-pET28b 
plasmid was transformed into BL21(DE3) (Stratagene). Transformed bacteria were incubated in 
LB media at 37ºC for growth, and then 16ºC for protein expression which was induced by 0.3 
mM IPTG. Cells were harvested by centrifuge and lysed by French Press. The supernatant 
containing PRMT1 protein was loaded onto the Ni-charged His6x-tag binding resin (Novagen) 
that was equilibrated with column buffer (25 mM Na-HEPES, pH 7.0, 300 mM NaCl, 1 mM 
PMSF, and 30 mM imidazole). Beads were washed thoroughly with column buffer, followed by 
washing buffer (25 mM Na- HEPES, pH 7.0, 300 mM NaCl, 1 mM PMSF, and 70 mM 
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imidazole), and protein was eluted with elution buffer (25 mM Na-HEPES, pH 7.0, 300 mM 
NaCl, 1 mM PMSF, 100 mM EDTA, and 200 mM imidazole). Different eluent fractions were 
checked by 12% SDS-PAGE, and PRMT1 concentration was determined by Bradford assay.  
4.4.3. Chemical crosslinking and Western blotting of PRMT1 oligomers 
To study the relationship between PRMT1 oligomerization and concentration, His6x-
rPRMT1 was diluted in the range of 0.012 μM ~ 3.13 μM with storage buffer (25 mM HEPES 
(pH 7.0), 250 mM NaCl, 1 mM EDTA, 10% glycerol, and 1 mM DTT) containing 0.1% Triton 
X-100, and incubated at 4 ºC overnight. Then PRMT1 was cross-linked with 0.025% (v/v) 
glutaraldehyde at room temperature for 5 min. The reactions were quenched by addition of SDS 
loading buffer, and PRMT1 proteins were separated by 8% SDS-PAGE followed by western blot 
detection, with anti-PRMT1 rabbit polyclonal IgG (Upstate) as the primary antibody and goat 
anti-rabbit IgG-HRP (Millipore) as the secondary antibody. After washing away the unbound 
probes, PRMT1 bands were visualized using the SuperSignal West Pico Trial Kit (Thermo 
Scientific). The film image was analyzed by Quantity One, and the molar fraction of PRMT1 
monomer, dimer and oligomer were plotted against PRMT1 concentration.  
4.4.4. Radioactive methyltransferase assay 
The methylation assays of different H4 peptides or protein were performed using 14C-
isotope labeled SAM at 30 °C. The reaction buffer contained 50 mM HEPES (pH 8.0), 50 mM 
NaCl, 1mM EDTA and 0.5 mM DTT. H4 substrate and [14C]-SAM were preincubated in the 
reaction buffer for 5 min prior to initiation of the methyl transfer reaction by adding PRMT1 
(0.01 μM typically). The reaction time was controlled under initial rate conditions such that 
typical reaction yields were less than 20%. The reaction was quenched by spotting the reaction 
mixture on P81 filter paper disc (Whatman). After the paper discs were washed with 50 mM 
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NaHCO3 (pH 9.0) and air dried, liquid scintillation counting was performed to measure the 
amount of methylated products. Values for Km and kcat were obtained by measuring the initial 
velocity of the reaction at various concentrations of one substrate and fixed saturating 
concentration of the other substrate (cofactor). The kinetic data were fitted to the Michaelis-
Menton equation using non-linear regression methods.  
4.4.5. Equilibrium fluorescent titration 
The Kd value for PRMT1 and the fluorescent peptide binding was measured by 
fluorescence anisotropy methods. Increasing concentrations of PRMT1 were added to a constant 
concentration of fluorescent peptide (0.2 μM) at 30ºC in the same buffer mentioned above. The 
anisotropy increase due to the formation of large ES complexes was recorded with a Fluoro-Max 
4 fluorimeter (Horiba Jobin Yvon). The excitation and emission wavelengths were set at 498 nm 
and 524 nm, respectively. Data were fit to eq 1, where P is the fluorescence anisotropy at a given 
concentration of PRMT1, A is the amplitude, and kd is the observed dissociation constant 
between PRMT1 (E) and H4 peptide (S).  
 
 
4.4.6. Stopped-flow fluorescence measurements 
The transient-state kinetics of association, dissociation and catalytic turnover were 
determined by stopped-flow fluorescence assays using several fluorescein-labeled H4 peptides 
(H4FL, H4FLme1, H4FLme2) as probes. Binding of the fluorescent peptide to PRMT1 (or 
PRMT1-cofactor complex) quenches the peptide fluorescence, while release of the peptide 
restores the fluorescence. The transient fluorescence signal change was detected at 30°C on an 
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Applied Photophysics stopped-flow equipment using an excitation wavelength of 495 nm and a 
long pass emission filter centered at 510 nm. Four to six shots were collected and averaged for 
each curve. For the association measurements, increasing concentrations of PRMT1 (2, 4, 6 μM), 
with or without 100 μM SAH were mixed with 0.4 μM of fluorescent peptide in the reaction 
buffer (50 mM HEPES (pH 8.0), 50 mM NaCl, 1 mM EDTA, 0.5 mM DTT). After averaging the 
shot data, the association time courses were fitted to a single exponential function (eq 2) when 
the cofactor was absent, or to a double exponential function (eq 3) when the cofactor was 
present. In eq 2 and 3, F is the fluorescence intensity at time t, A is the amplitude of the 
fluorescence change, and kn are the rate constants. The observed rate constants were plotted 
against PRMT1 concentration, and the data were fit to eq 4 (in the absence of SAH) or eq 5 (in 
the presence of SAH) to derive the association rate constants kon or k1, respectively. For eq 5, k1 
and k-1 are the association and dissociation rate constants, and k2 and k-2 are the forward and 
reverse rate constants of phase 2. 
                                        F = A*exp(-k*t) + C                                                       (2) 
                                    F = A1*exp(-k1*t) + A2*exp(-k2*t) + C         (3) 
                                    kobs = kon*[PRMT1] + koff                                       (4) 
                                    kobs = k1*[PRMT1] + k-1 + k2 + k-2                     (5) 
For the dissociation rate constant measurements, 0.4 μM fluorescent peptide was 
prebound to 2 μM PRMT1 (with or without 100 μM SAH/SAM), and the complex was rapidly 
mixed with 50 μM unlabeled H4(1-20) peptide to trap the free PRMT1. The averaged shot data 
were fitted to eq 2 when the cofactor is absent or to eq 3 when the cofactor is present. Here k (or 
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k1) is the dissociation rate constant (koff), and k2 reflects the rate constant for a putative 
conformational change before substrate release. 
For PRMT1 methylation kinetics in single turnover conditions, H4FL or H4FLme1 
peptides were used to probe the reaction rate for transfer of both methyl groups (H4FL) or only 
the second methyl group (H4FLme1). In these reactions, 2 μM PRMT1 and 100 μM SAM were 
mixed with 0.4 μM H4FL or H4FLme1 in the reaction buffer mentioned above. The methylation 
time course exhibited two distinct kinetic phases, and was fitted to a double exponential function 
(eq 3), where the observed k2 likely reflects the methyl transfer rate constant. The rate constant 
for transfer of the first methyl group (k1’) is calculated from eq 6, where ktot (the total rate 
constant for transfer of two methyl groups) is obtained from H4FL methylation time course, and 
k2’ (the rate constant for transfer of the second methyl group) is obtained from H4FLme1 
methylation time course.  
1/ktot = 1/k1’ + 1/k2’                                       (6) 
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CHAPTER 5 
HISTONE H4 ACETYLATION DIFFERENTIALLY MODULATES ARGININE 
METHYLATION BY AN IN CIS MECHANISM 
(This work is mainly based on the published paper, J. Biol. Chem. 286 (2011) 20323-34. In this 
project, the author is obliged to Dr. Juxian Wang for her contribution to NMR calibration of the 
peptide concentrations and part of PRMT1 activity tests, to Sabrina Asher for her contribution to 
the peptide preparation, and to Dr. Ivaylo Ivanov and Carlo Guardiani for the molecular 
modeling of peptide structures.)  
5.1. Introduction 
The nucleosome is the fundamental structural unit of chromatin, in which 146 base pairs 
of DNA are wrapped around an octamer of two molecules of each of the four core histones 
(H2A, H2B, H3 and H4 proteins). Widespread post-translational modifications (PTMs) of the 
histone proteins have been identified, including acetylation, phosphorylation, methylation, 
ubiquitination, and ribosylation (5, 122). The types and sites of modifications and the specific 
functions of these PTM marks in modulating chromosomal remodeling and DNA function have 
been intensively studied in recent years. In particular, significant amounts of data have pointed 
out the functional correlation of histone modification with transcriptional regulation (123, 124). 
While certain modifications are shown as representative marks of active transcription (e.g., 
H3K4 methylation, H3K36 methylation, H3 and H4 lysine acetylation, and H2B ubiquitylation), 
some others are correlated with transcriptional repression (e.g., H3K9 methylation, H3K27 
methylation, H4K20 methylation, and H2A ubiquitylation) (44, 125). Of importance, many 
histone PTM marks co-occurring in the same histones can be synergistic or antagonistic with one 
another, forming complicated combinatorial histone modification patterns which have been 
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proposed to function as a set of multivalent “histone codes” that promote or repress various 
chromosomal transactions that occur in the cell (5, 126, 127). Histone PTM patterns provide a 
biochemical index for individual cell type and disease state, and correlate with particular 
biological phenomena of the cell (128-131). Given the abundance of histone modification marks 
and the dynamic changes of histone modification patterns in response to cell types and 
differentiation contexts, it remains a challenging biological theme to illuminate the molecular 
basis of how histone codes and code networks are biochemically created and manifest their 
downstream impacts on chromatin function (127). 
The N-terminal tail of histone H4 is heavily modified at several sites, including Ser-1 
phosphorylation, Arg-3 methylation, Lys-5, -8, -12, -16, -20 acetylation (i.e., K5ac, K8ac, K12ac 
and K16ac), and lys-20 methylation (40, 132-138). These modifications have been shown to be 
very dynamic, and distinct histone modification patterns have been observed in different cell 
types, or at different developmental stages of life, or in different phases of cell cycle (128, 129, 
139, 140). For example, Pesavento et al. (140) characterized H4 modification by using Top-
down mass spectrometric approaches coupled with two-dimension liquid chromatography and 
identified 42 forms of H4 in HeLa cells each of which contains different modification patterns. 
Coon and coworkers used mass spectrometry methods to identify 74 histone H4 isoforms in 
differentiating human embryonic stem cells (139). There is a strong need to understand how 
these combinatorial PTM patterns are established at the histone tail. 
Acetylation represents one of the most frequent modifications at the H4 tail. The 
acetylation is introduced by several histone acetyltransferases (HATs), including p300/CBP 
(134, 141), Tip60 (142, 143), and yeast protein Esa1 (144). For example, both p300/CBP and 
Esa1 acetylate H4 at K5, 8, 12, and 16 in vitro, and in the context of a nucleosome, acetylation of 
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K5 and K8 by p300 is preferred (134, 141). K16 is a preferred acetylation site by the MOF 
subunit of the MSL and NSL complexes (145, 146). Histone acetylation is reported to affect the 
assembly of higher order nucleosome structures (147) and is generally proposed to coactivate 
gene expression. Since there are four major acetylation sites at the H4 tail, i.e., K5, 8, 12, 16, 
HAT catalysis can produce a total of 16 acetylated H4 isoforms. Effort is needed to address 
which acetylation site and which acetylation combination play predominant roles in determining 
the transcriptional status of gene loci. H4K16 acetylation has been particularly shown to be a 
hallmark of open chromatin and transcriptional activation (148). It is noteworthy to point out that 
different acetylation patterns may be correlated with different functions. For example, K5 and 
K12 acetylations are known to be predeposition marks, highly enriched prior to chromatin 
assembly during S-phase (149, 150). Possibly, the acetylation event may affect gene expression 
by influencing or even determining other modifications at the histone tail. This is especially true 
given that histone acetylation has been demonstrated in several studies to be an early event and 
occur upstream of other modifications (140, 151). 
Here, we investigated how different H4 acetylations and their combinations affect 
methylation of H4 at Arg-3 (i.e., H4R3me) at the biochemical level. Protein arginine methylation 
is catalyzed by protein arginine methyltransferases (PRMTs) which are S-adenosyl methionine 
(AdoMet, SAM)-dependent enzymes and generally classified into type I and type II families. 
PRMT1 is the predominant member of type I PRMTs and PRMT5 is a representative member of 
type II PRMTs in mammalian cells (Figure 5.1). Type I PRMTs are able to transfer up to two 
methyl groups from the cofactor AdoMet to one single terminal nitrogen of the guanidino group 
of specific arginine residues in a protein substrate, resulting in ω-NG-monomethylarginine 
(MMA) and ω-NG,NG-asymmetric dimethylarginine (ADMA) products (19, 21, 23, 24). In 
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contrast, Type II PRMT enzymes place one methyl group on each of the two terminal guanidino 
nitrogens to form MMA and ω-NG, N’G-symmetric dimethylarginine (SDMA) products (24, 26, 
27). Due to the lack of structural information, it is still poorly understood how the 
regiospecificity in methylated products is achieved. At the H4 tail, both PRMT1 and PRMT5 are 
able to methylate H4R3 in vivo. Of significance, the biological impact of H4R3 methylation by 
PRMT1 is opposite to that of PRMT5: PRMT1-mediated dimethylation of R3 is correlated with 
gene activation (40), but the methylation of H4R3 by PRMT5 is in many cases associated with 
gene repression (76). Our biochemical data show that PRMT1 recognizes and methylates H4 
substrates that contain different acetyl marks in a very distinct manner from that of PRMT5, thus 
providing a molecular insight into the mechanism of how PRMT1 and PRMT5 target the 
chromatin template and how acetylation contributes to the establishment of H4 modification 
patterns or codes by an cis-acting mechanism. This finding also unveils a clear distinction 
between type I PRMT and type II PRMT with respect to the mode of substrate specificity 
regulation. 
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Figure 5.1. Methylation of H4R3 by PRMT1 and PRMT5. 
5.2. Results 
5.2.1. Design, synthesis, and characterization of modified H4 peptide library. 
The N-terminal tail of H4 is subject to many PTMs including R3 methylation and 
acetylation at K5, 8, 12, and 16 sites. To quantitatively evaluate the in-cis effect of acetylation 
marks on R3 methylation, we designed a library of H4 peptides containing the first 20 amino 
acids that incorporate all the 16 possible acetylation combinations, including 1 uncetylated, 4 
monoacetylated, 6 diacetylated, 4 triacetylated, and 1 tetraacetylated forms (Table 5.1). All 
peptides are N-terminally capped with acetic anhydride because virtually all H4 proteins are N-
terminally acetylated in vivo (129, 139, 140, 152). These peptides are used as substrates of 
PRMT1 and PRMT5 to evaluate how different acetylation combinations affect the methylation 
of R3 catalyzed by these two enzymes. It is worthwhile to stress that our data and others have 
fully determined that the N-terminal peptide sequence represents an authentic substrate of 
PRMTs and its catalytic properties are very similar to that of the full-length H4 protein (33). All 
the peptides were synthesized using the standard Fmoc SPPS protocols, purified on C-18 
reversed phase HPLC column, and confirmed with MALDI-MS as previously described (86). 
Table 5.1. Sequences of synthetic H4 peptides. The ac symbol stands for acetyl group. 
Abbreviation Sequence MW calculated 
MW 
measured 
A. wt H4  ac-SGRGKGGKGLGKGGAKRHRK 2034.2 2034.1 
B. H4K5ac  ac-SGRGKacGGKGLGKGGAKRHRK 2076.2 2076.1 
C. H4K8ac  ac-SGRGKGGKacGLGKGGAKRHRK 2076.2 2076.2 
D. H4K12ac  ac-SGRGKGGKGLGKacGGAKRHRK 2076.2 2076.2 
E. H4K16ac  ac-SGRGKGGKGLGKGGAKacRHRK 2076.2 2076.3 
F. H4K5ac8ac  ac-SGRGKacGGKacGLGKGGAKRHRK 2118.2 2118.1 
G. H4K5ac12ac  ac-SGRGKacGGKGLGKacGGAKRHRK 2118.2 2118.4 
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H. H4K5ac16ac  ac-SGRGKacGGKGLGKGGAKacRHRK 2118.2 2118.2 
I. H4K8ac12ac  ac-SGRGKGGKacGLGKacGGAKRHRK 2118.2 2118.5 
J. H4K8ac16ac  ac-SGRGKGGKacGLGKGGAacKRHRK 2118.2 2118.1 
K. H4K12ac16ac  ac-SGRGKGGKGLGKacGGAKacRHRK 2118.2 2118.3 
L. H4K5ac8ac12ac  ac-SGRGKacGGKacGLGKacGGAKRHRK 2160.2 2160.6 
M. H4K5ac8ac16ac  ac-SGRGKacGGKacGLGKGGAKacRHRK 2160.2 2160.7 
N. H4K5ac12ac16ac  ac-SGRGKacGGKGLGKacGGAKacRHRK 2160.2 2160.3 
O. H4K8ac12ac16ac  ac-SGRGKGGKacGLGKacGGAKacRHRK 2160.2 2160.6 
P. H4K5ac8ac12ac16ac  ac-SGRGKacGGKacGLGKacGGAKacRHRK 2202.2 2202.4 
 
Since synthetic peptides typically contain varying amounts of TFA counter ions as a 
result of HPLC purification, we sought to determine the accurate concentration of each H4 
peptide prior to enzymatic analysis. The NMR spectra of H4 peptides show two very 
characteristic peaks at 7.4 and 8.7 ppm which come from the imidazole side chain of His-18 
(Figure 5.2). We used the integration ratio between these two peaks and the methyl peak of 
standard reagent DSS to calibrate the concentration of each H4 peptide. A typical 1D 1H-NMR 
spectrum used for calibration of H4 peptide concentration is shown in Figure 5.2. The use of 
NMR calibration to obtain the accurate concentration of H4 peptides is technically critical for 
accurately quantifying and comparing the effect induced by individual acetylation marks. As a 
matter of fact, varying degrees of difference were observed between weight-based concentrations 
and NMR-calibrated concentrations (data not shown). 
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Figure 5.2. A typical NMR spectrum used for calibration of H4 peptide 
concentration. The NMR solution contained 4.5 mM of H4K16ac peptide and 1 mM of DSS in 
D2O. 
5.2.2. Impact of H4 acetylation on PRMT1-catalyzed R3 methylation. 
Arginine 3 of H4 is methylated by PRMT1. However, the potential effect of acetylation 
at K5, 8, 12, and 16 on R3 methylation is not clear. The four acetylations at K5, 8, 12, 16 
generate multiple combinations. It remains to determine whether individual combination marks 
affect R3 methylation differentially or in a similar manner and which acetyl mark predominantly 
modulates R3 methylation. 
With the purified H4 library peptides, we tested PRMT1-catalyzed methylation of 
individual H4 peptides each of which contains a unique acetylation pattern. The methylation 
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reaction was composed of 0.1 µM of PRMT1, 20 µM of [14C]-AdoMet and 100 µM of each 
substrate, and the reaction was allowed to proceed for 10 min. The reaction mixtures were 
resolved on 16% SDS-PAGE and the methylated products were visualized by phosphorimaging 
and quantitated using ImageQuant software (Figure 5.3). At first glance of the experimental data, 
it is apparent that some acetylation combinations decrease but some others increase the level of 
R3 methylation. In particular K5 acetylation is detrimental to R3 methylation, which alone 
decreases R3 methylation by 30%. In combination with other lysine acetylations, e.g., with 
K8ac, or K8ac and K12ac, the repressive effect of K5ac is even stronger; the degree of 
repression reaches 3 and 5 folds, respectively. On the other hand, K16ac leads to a positive 
impact on R3 methylation. K16 acetylation alone increases the PRMT activity by 30%. The 
majority of H4 peptides that contain the K16ac mark (except M and P) are slightly better 
substrates of PRMT1. For instance, if K16ac coexists with K5ac, K8ac or K12ac, the activation 
effect is dominant. Compared to K5ac and K16ac, the effect of K8ac and K12ac in regulating R3 
methylation seems quite marginal by itself and is influenced by the presence of K5ac or K16ac 
mark. For example, a repressive effect is observed when K8ac co-presents with K5ac, but a 
positive effect is observed when K8ac co-presents with K16ac. Overall, these data support that 
K5ac and K16ac are two counteractive modification marks that affect R3 methylation in opposite 
ways: K5ac is the predominant factor that negatively impacts R3 methylation, and K16ac 
positively modulates R3 methylation by PRMT1. 
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Figure 5.3. Effects of lysine acetylation on Arg-3 methylation by PRMT1.  The 
reaction buffer contained 50 mM of HEPES (pH 8.0), 10 mM of NaCl, and 1 mM of DTT.  The 
concentration of PRMT1, [14C]-AdoMet and H4-20 were 0.1 µM, 20 µM and 100 µM, 
respectively. The reaction time was 10 min. 
To understand the mechanism by which K5ac and K16ac affect R3 methylation by 
PRMT1, we measured the steady-state kinetic parameters of unacetylated and several acetylated 
H4 peptides. The data shown in Table 5.2 reveal that for the methylation of H4K5ac peptide, the 
kcat decreases by half but there is little change in Km. These data suggest that acetylation of K5 
does not cause explicit changes in the substrate binding and recognition by PRMT1. Likely, the 
positively charged K5 is required for a methyl transfer step in the catalytic pathway of PRMT1 
and acetylation of K5 blocks this key step in the methyl transfer reaction as reflected in its effect 
on kcat. On the other hand, acetylation of K16 affects Km more than kcat and V/K is increased from 
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1.78 to 3.22 min-1μM-1. Thus, K16ac appears to increase the affinity of enzyme-substrate 
association, but has little effect on the catalytic step. 
Table 5.2. Steady-state kinetic parameters of PRMT1 catalysis. The methylation of 
each peptide by PRMT1 was tested with the radioactive filter binding assay. Varied 
concentrations of peptide (0 to 20 μM) and 15 µM of [14C]-AdoMet were incubated at 30ºC for 5 
min in the reaction buffer (50 mM HEPES, pH 8.0, 10 mM NaCl and 1 mM DTT). The reaction 
was initiated with PRMT1. The methylated products were purified on to P81 filter paper and 
quantified by liquid scintillation. Calculated methylation rate was plotted as a function of peptide 
concentration and the data were fitted with Michaelis-Menton equation.  
Substrates Km, μM kcat, min-1 V/K, min-1μM-1 
A wt H4-20 0.34 ± 0.05 0.64 ± 0.13 1.78 ± 0.69 
B H4(1-20)K5ac 0.37 ± 0.06 0.32 ± 0.01 0.86 ± 0.14 
C H4(1-20)K8ac 0.58 ± 0.10 0.50 ± 0.02 0.86 ± 0.15 
D H4(1-20)K12ac 0.27 ± 0.05 0.47 ± 0.01 1.74 ± 0.32 
E H4(1-20)K16ac 0.23 ± 0.05 0.74 ± 0.06 3.22 ± 0.75 
H H4(1-20)K5acK16ac 3.29 ± 0.53 1.02 ± 0.07 0.31 ± 0.05 
J H4(1-20)K8acK16ac 1.11 ± 0.17 1.33 ± 0.06 0.84 ± 0.19 
K H4(1-20)K12acK16ac 0.38 ± 0.07 0.77 ± 0.03 2.06 ± 0.38 
 
Our biochemical data reveal that the impact of H4 acetylation on PRMT1-mediated R3 
methylation depends on the individual pattern of acetylation combination. The clear observation 
is that K5ac is the predominant modification mark that negatively impacts on R3 methylation by 
PRMT1 (Figure 5.3). The lower kcat of H4K5ac methylation with regard to that of the wild type 
H4 suggests that the acetyl group on K5 produces a steric or hydrophobic hindrance in the active 
site, reducing the ability of PRMT1 in methylating H4R3. Acetylation at K8 and K12 seems to 
have minimal effects on R3 methylation, but their presence can augment the impact of K5ac or 
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K16ac. Interestingly, K16ac enhances R3 methylation, and to some degree antagonizes the effect 
of K5 acetylation. This is slightly different from the result of a previous study showing that all 
forms of H4 acetylation repress R3 methylation (40). The difference is likely caused by the 
methods used in peptide concentration determination. In our experiments, the peptide 
concentrations were accurately calibrated by NMR technique, but in the previous study peptide 
concentrations were weight-based. Despite this technical difference, the repressive impact of H4 
acetylation on type I methylation of R3 was clearly observed in several acetylated H4 forms 
containing the K5ac mark. It is important to mention that our biochemical results coincide well 
with the in vivo data that methylated R3 was found to be present with K16ac mark in many H4 
isoforms (139, 140) and coexistence of K16ac with R3me was observed in higher histone H4 
population than any other acetylated H4 isoforms (140). 
The observed acetylation effect also suggests valuable clues about PRMT1-H4 
interaction. It seems reasonable that K16ac affects Km, but not kcat, given the remoteness of this 
residue to R3 along the H4 backbone chain. The prominent impact of K16 acetylation on R3 
methylation is in good agreement with a previous study showing that the amino acid residues on 
the H4 tail distal from R3 (i.e., aa 16-20) interact with PRMT1 and contribute to substrate 
recognition (153). The crystal structure of PRMT1 highlights that an acidic area exists on the 
surface of PRMT1 (80) and suggests that positive charges of substrates are needed for binding to 
the enzyme. Here, our data demonstrate that electrostatic interaction does not seem to be the sole 
factor determining the PRMT1⎯substrate interaction since K16 acetylation favors the 
methylation at R3. This is also supported by the fact that, in H2A, a PRMT1 substrate with 
similarity to H4, threonine is placed at the equivalent position of H4K16.  
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5.2.3. Impact of H4 acetylation on PRMT5-mediated R3 methylation.  
In addition to asymmetric dimethylation by PRMT1, H4R3 can be symmetrically 
dimethylated by PRMT5 in vivo. Of great interest is that these two types of dimethylation in 
many cases are correlated with opposite functions in gene transcriptional regulation: PRMT1 
activates gene expression but PRMT5 represses transcription (40, 76). To understand the 
molecular basis of such functional oppositeness, we have examined how H4 acetylation affects 
symmetric dimethylation of H4R3 by PRMT5. First, we subjected the 16-mer H4 library 
peptides to PRMT5 catalysis under the similar condition as the methylation by PRMT1. 
Concentrations of PRMT5, [14C]-AdoMet and H4 peptide were maintained at 0.1 µM, 30 µM 
and 200 µM respectively, and the reaction proceeded for 1 h. The methylated products were 
resolved on SDS-PAGE and analyzed by phosphorimaging. As shown in Figure 5.4, intriguingly, 
most acetylated H4 peptides are better methylated by PRMT5 than the unacetylated H4. This is 
in stark contrast with the methylation catalyzed by PRMT1, in which the fully acetylated H4 is a 
poor substrate. The preference of acetylated H4 by PRMT5 is further validated by the data of kcat 
and Km measurement (Table 5.3). In particular, K5ac upregulates the value of kcat, suggesting 
that this modification mark provides favorable contact with the active site of PRMT5 to facilitate 
methyl transfer. Also, K16ac increases Km, suggesting that this distal modification mark weakens 
the binding affinity of H4⎯PRMT5. Thus, the impacts of K5ac and K16ac are opposite to that 
of PRMT1 catalysis. 
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Figure 5.4. Effects of acetylation on R3 methylation catalyzed by PRMT5. Reaction 
buffer contained 50 mM of HEPES (pH 8.0), 10 mM of NaCl, and 1 mM of DTT. Concentration 
of PRMT5, [14C]-AdoMet and H4 peptide were 0.1 µM, 30 µM and 200 µM respectively. The 
reaction time was 1 h. 
Table 5.3. Kinetic parameters of PRMT5 catalysis. The catalytic activity of PRMT5 
on each peptide was tested with the radioactive filter binding assay. Varied concentrations of 
peptide (0 to 10 μM) and 30 µM of 14[C]-AdoMet were incubated at 30ºC for 5 min in the 
reaction buffer (50 mM HEPES (pH 8.0), 50 mM NaCl, 1 mM EDTA and 0.5 mM DTT) prior to 
the addition of PRMT5. The methylated products were loaded onto P81 filter paper and 
quantified by liquid scintillation. Calculated methylation rate was plotted as a function of peptide 
concentration and the data were fitted with Michaelis-Menton equation. 
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Substrates Km, μM kcat, min-1 V/K, min-1μM-1 
A wt H4-20 0.63 ± 0.11 0.043 ± 0.002 0.068 ± 0.012 
B H4(1-20)K5ac 0.38 ± 0.08 0.079 ± 0.003 0.21 ± 0.044 
C H4(1-20)K8ac 0.66 ± 0.14 0.042 ± 0.003 0.064 ± 0.014 
D H4(1-20)K12ac 0.52 ± 0.13 0.049 ± 0.003 0.094 ± 0.024 
E H4(1-20)K16ac 1.20 ± 0.16 0.048 ± 0.002 0.040 ± 0.006 
 
5.2.4. Impact of H4 acetylation on PRMT1 and PRMT5 activity using H4 protein and 
nucleosome as substrates.  
So far, we used a 16-mer H4 peptide library comprising different acetylation patterns to 
dissect the detailed effects of H4 acetylation on the activity of PRMT1 and PRMT5. To further 
confirm these results, we investigated methylation of H4 at the protein level by these two PRMT 
members. In the experiment, acetylation of recombinant H4 protein was first introduced by 
incubation with acetyl-CoA and HAT proteins p300 or MOF. Next, the acetylated H4 protein 
was subject to PRMT1 and PRMT5 catalysis using [14C]-AdoMet as the methyl donor. The 
reaction mixtures were then resolved on SDS-PAGE and the methylated H4 band was visualized 
by storage phosphor imaging. As seen in Figure 5.5, it is clear that acetylation on H4 protein 
inhibited its methylation catalyzed by PRMT1, but promoted PRMT5-mediated methylation. 
These data coincide well with the peptide methylation data showing that hyperacetylation of H4 
inhibited PRMT1 activity but potentiates PRMT5 activity. We also attempted to test such effects 
by using nucleosomal substrates. The reconstituted nucleosome was assembled from the 
recombinant core histone proteins and a 208-bp 5SrDNA by using the EpiMark protocol (Figure 
5.6). However, we found that H4 protein in the context of nucleosome or even in the presence of 
DNA (2:1 ratio as is in the nucleosome) was not appreciably methylated by PRMT1 or PRMT5 
in our reaction conditions (Figure 5.7). This important observation implicates that DNA 
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(especially the unassembled free DNA) poses a physical barrier between nucleosomal histone 
and PRMTs, preventing the N-terminal tails of the core histones from being methylated by 
PRMTs. Quite likely, arginine methylation of the chromatin template by PRMTs would require 
additional accessory proteins or factors in vivo. Another possibility is that the 5SrDNA used here 
is not well-suited for nucleosome assembly. If we switch to another nuclear DNA fragment the 
methylation result could be different. This DNA effect should be further investigated. 
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Figure 5.5. Acetylation on H4 protein inhibits its methylation by PRMT1, while 
promotes its methylation by PRMT5. (A) p300-acetylation inhibits H4 methylation by 
PRMT1. H4 protein was incubated with Acetyl-CoA in the absence or presence of p300 before 
submission to PRMT1 methylation with [14C]-AdoMet. Methylated H4 bands were separated by 
15% SDS-PAGE and visualized by storage phosphor scan, which is the same method as for B, C, 
and D. (B) p300-acetylation promotes H4 methylation by PRMT5. H4 protein was incubated 
with Acetyl-CoA in the absence or presence of p300 before submission to PRMT5 methylation. 
(C) MOF-acetylation inhibits H4 methylation by PRMT1. H4 protein was incubated with Acetyl-
CoA in the absence or presence of MOF before submission to PRMT1 methylation. (D) MOF-
A                                        B                                     C                                   D              
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acetylation promotes H4 methylation by PRMT5. H4 protein was incubated with Acetyl-CoA in 
the absence or presence of MOF before submission to PRMT5 methylation. 
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Figure 5.7. Assembled nucleosome cannot be methylated by PRMT1 or PRMT5 in 
vitro. The methylation of the nucleosome was tested with PRMT1 and PRMT5 in vitro and 
compared to H4 protein. 0.21 μM nucleosome or 0.42 μM H4 was incubated with 10 μM [14C]-
Figure 5.6. Gel shift assay of the 
assembled nucleosome. The nucleosomes 
were assembled using the EpiMark Nuceosome 
Assembly kit with purified recombinant core 
histones and 5SrDNA (208 bp) according to the 
manufacturer’ protocol. The assembled 
nucleosomes were checked by the Gel Shift 
Assay with 6% native acrylamide gel 
electrophoresis. 
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SAM and methyltransferase (0.01 μM PRMT1 or 0.1 μM PRMT5) at 30°C for 65 min, then the 
reaction was quenched by SDS loading buffer. The PRMT1 methylation of the recombinant core 
histones and the mixture of H4 protein and 5SrDNA (2:1 mole ratio) were also tested as controls. 
The methylated protein was separated by 17% SDS-PAGE and visualized by storage phosphor 
scan. 
5.2.5. The structural changes of H4 induced by acetylation.  
It is of great interest to understand the structural basis of the distinct effect of lysine 
acetylation on R3 methylation, especially K16ac which is remote from the methylation site. Thus 
far, there is no information available on whether and how lysine acetylation changes the structure 
of the histone tails in the nucleosome. It could be possible that acetylation causes changes in the 
secondary structure of the H4 tail which affects its interaction with PRMTs. To examine whether 
there are any structural changes in H4 following lysine acetylation, we measured CD spectra of 
wild-type unacetylated H4 peptide (A) and the tetraacetylated H4 peptide (P). In particular, the 
CD spectra were measured at different concentrations of TFE (0⎯80%) to determine whether 
hydrophobicity of the solvent environment affects the secondary structures (Figure 5.8A and 
5.8B). The collected CD spectra were analyzed by Dichroweb, an online server for protein CD 
spectra deconvolution (154) to calculate secondary structure contents (helix, strand, turn, and 
random coil) for each peptide sample. As shown in Figure 5.8C, the contents of random coils 
occupied a high percentage in both A and P. This is not surprising given that the N-terminal 
sequence of H4 is invisible in the crystal structures of nucleosome (155), suggesting it is largely 
in disordered states. However, we clearly noticed that for the H4 peptide with tetraacetyl marks 
(i.e. P), the content of helix and strand became appreciably higher than that of the unacetylated 
H4, namely, 36% versus 13%. This suggests that lysine acetylation renders the H4 peptide in 
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more structured states. Furthermore, it was observed that as TFE concentration increased, the 
amount of ordered secondary structures appeared to go higher (Figure 5.8D), implicating that 
hydrophobic environment favors formation of ordered structures in H4 N-terminal region. 
Overall, these data demonstrate that lysine acetylation promotes the tendency of H4 tail to form 
ordered secondary structures. 
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Figure 5.8. Secondary structure analysis of unacetylated H4 peptide (A) and 
tetraacetylated H4 peptide (P). CD spectra of unacetylated H4 (panel A) and tetraacetylated H4 
(panel B) were measured at different concentrations of TFE (0 ~ 80%) in 20 mM Tris-HCl buffer 
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(pH 7.4): black, 0% TFE; blue, 5% TFE; orange, 20% TFE; green, 40% TFE; red, 80% TFE. The 
CD data were analyzed by Dichroweb to calculate secondary structure compositions. Panel C: 
column graph showing the distribution of secondary structures for the two peptides at 20% of 
TFE. Panel D: the changes in the composition of ordered structures (i.e. helix and strand) for 
each peptide with TFE concentration. 
 
To further confirm the structural impact of lysine acetylation on the H4 sequence, we 
conducted a simulation analysis of the unacetylated H4 and tetraacetylated H4 peptides. The 
modeling was conducted on the Jaguar parallel machine by using the AMBER suite of programs. 
The simulations show that a dramatic structural change occurs upon lysine acetylation. The first 
evidence for the structuring effect of tetra-acetylation is provided by the distribution of the radius 
of gyration plot (Figure 5.9a). This distribution appears relatively flat and broad (average: 12.16 
Å, variance: 6.06 Å2) in the case of the wild-type peptide but undergoes a shift towards lower 
values when the peptide is acetylated. This observation is suggestive of a transition from a 
population of extended, predominantly random coil peptides to a population of compact and 
more globular structures. Figure 5.9b shows that in the wild type peptide, the distribution of the 
pairwise backbone RMSD had an average of 7.67 Å and a variance of 4.20 Å2. These values shift 
to 4.93 Å and 2.36 Å2 respectively for the acetylated peptide suggesting that acetylation creates a 
more homogeneous population with a smaller number of structural families. This prediction is 
confirmed by clustering analysis where a cutoff as large as 9.0 Å was necessary to group the wild 
type population into 14 clusters whereas a cutoff of 6.0 Å was sufficient to generate 18 clusters 
in the case of the acetylated peptide. 
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Figure 5.9. Simulated structural changes upon tetraacetylation of the N-terminal H4 
tail. Panel (a): Probability distribution of the radius of gyration of the unacetylated and tetra-
acetylated H4 peptides. Panel (b): probability distribution of the pairwise backbone RMSD of the 
structures of the equilibrium population. 
 
The clusters of the equilibrium population of the unacetylated peptide roughly belong to 
three main structural groups whose representative conformations can be seen in Figure 5.10. The 
first group (50% of structures) is mainly populated by extended conformations where lysine and 
arginine side chains stick out from the axis of the molecule to minimize electrostatic repulsion. 
109 
 
 
The second group (24% of structures) is populated by distorted hairpin-like conformations where 
the standard β-hairpin is replaced by a swollen bubble-like loop arising from the repulsion 
between lysines and arginines. Finally, the third group (26% of structures) comprises extended 
conformations featuring a small loop at one or both ends that can be regarded as intermediates in 
the interconversion pathway between the structures of the first two groups. 
 
Figure 5.10. Clustering of the equilibrium population of the unacetylated (left 
column) and tetraacetylated (right column) H4 peptides. Rows (a), (b), (c) show the 
representative conformations of clusters 1, 2 and 3 respectively. The color code represents 
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different secondary structural elements as identified throuh a DSSP analysis (156). Purple: α-
helix; Blue: 310-helix; Green: turn; Orange: random Coil. 
 
Three major classes can also be detected in the equilibrium population of the 
tetraacetylated H4 peptide based on the results of the clustering analysis (Figure 5.10). The motif 
of the first class, including 59% of structures, is represented by three 310 helices orthogonal to 
each other and is therefore somewhat reminiscent of the hairpin-like conformations of group 2 of 
the unacetylated peptide. It can therefore be suggested that acetylation induces the stabilization 
and structuring of a conformation that was already present in the population of the unacetylated 
species. As a final remark, we note that this motif brings the N- and C- termini of the H4 tail 
peptide close to one another thus suggesting a possible mechanism through which the acetylation 
of K16 affects the methylation propensity of R3 from a distal region of the molecule. The second 
class, amounting to 24% of the structures, features extended conformations composed by two or 
three 310 helices linked by turns. The third class (17% of structures) is characterized by an L-
shaped motif composed by two orthogonal 310 helices linked by a central turn region, which, 
similarly to the case of the unacetylated peptide, can be considered as intermediates between the 
conformations of the former two classes. In fact, in conditions of dynamic equilibrium, it can be 
suggested that the extended conformations of Class 2 can bend in the L-shaped conformation of 
Class 3 which finally completes the folding in the orthogonal arrangement of helices of Class 1. 
5.3. Conclusion 
To dissect the interplaying relationship between different histone modification marks, we 
investigated how individual lysine acetylations and their different combinations at the H4 tail 
affect Arg-3 methylation in cis. Our data reveal that the effect of lysine acetylation on arginine 
111 
 
 
methylation depends on the site of acetylation and the type of methylation. While certain 
acetylations present a repressive impact on PRMT-1 mediated methylation (type I methylation), 
lysine acetylation generally is correlated with enhanced methylation by PRMT5 (type II 
dimethylation). In particular, Lys-5 acetylation decreases activity of PRMT1 but increases that of 
PRMT5. Furthermore, circular dichroism study and computer simulation demonstrate that 
hyperacetylation increases the content of ordered secondary structures at the H4 tail region. 
These findings provide new insights into the regulatory mechanism of Arg-3 methylation by H4 
acetylation, and unravel that complex intercommunications exist between different PTM marks 
in cis. The divergent activities of PRMT1 and PRMT5 with respect to different acetyl-H4 
substrates suggests that type I and type II PRMTs use distinct molecular determinants for 
substrate recognition and catalysis. 
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Figure 5.11. Summary of the effects of lysine acetylation on R3 methylation in H4. 
Acetylation of the N-terminal H4 tail reciprocally affects PRMT1-mediated Arg-3 methylation 
and PRMT5-mediated Arg-3 methylation. A solid line means that the effect of acetylation is 
appreciably strong and a dotted line means that the effect of acetylation is relatively weak. 
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5.4. Experimental 
5.4.1. Design and synthesis of acetylated H4 peptides 
The amino-terminal peptide of histone H4 containing the first 20 amino acid residues and 
different acetylation patterns were synthesized using Fmoc [N-(9-fluorenyl) methoxycarbonyl]-
based solid phase peptide synthesis (SPPS) protocols on a PS3 peptide synthesizer (Protein 
Technology. Tucson, AZ). Each amino acid was coupled to the solid phase by using 4 
equivalents of amino acid/HCTU [O-(1H-6-Chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate] (Novabiochem, Darmstadt, Germany). Fmoc was 
deprotected with 20% v/v piperidine/DMF. The N-terminal amino acid was acetylated with 
acetic anhydride. The peptide was cleaved from the Wang resin by incubating the resin in a 
cleavage solution consisted of 95% trifluoroacetic acid (TFA), 2.5% H2O and 2.5% 
triisopropylsilane for 3 h. Peptides were precipitated in cold ether and then pelleted by centrifuge 
at 3000 RPM for 10 min. After washing with ether, crude peptides were collected and purified 
using a Varian Prostar instrument equipped with a C-18 Reversed-phase High Performance 
Liquid Chromatography (RP-HPLC) column. 0.05% TFA-containing water and 0.05% TFA-
containing acetonitrile were two mobile phases used in gradient purification. The purity and 
identity of purified peptides were confirmed by analytical HPLC and MALDI-MS. 
5.4.2. Calibration of peptide concentrations with NMR 
The accurate concentration of each peptide was determined by measuring its 1D 1H-
NMR spectra with external standard on a Bruker Avance 400 MHz instrument. For each NMR 
sample, a D2O solution was prepared containing 4.5 mM (weight-based) of individual H4 
peptide and 1 mM of 4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS), respectively. The 1H 
NMR spectra were collected at room temperature. The integration ratio between the proton peak 
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of DSS at 0 ppm and the two proton peaks of the imidazole group of the histidine residue, i.e., 
His-18 (δ = 7—9 ppm) was measured to calculate the real concentration of each H4 peptide 
sample. 
5.4.3. Protein expression and purification 
Recombinant His-tagged rat PRMT1 was expressed in E. coli and purified with Ni-
charged His6x-tag binding resin (Novagen). The PRMT1-pET28b(+) plasmid was transformed 
into E. coli BL21(DE3) (Stratagene) by heat shock. Bacteria were incubated in LB media at 37ºC 
for growth, and 16 ºC for protein expression (induced by IPTG 0.3 mM). Cells were harvested by 
centrifuge and lysed by French Press. The supernatant containing PRMT1 protein was loaded to 
the Ni-charged His6x-tag binding resin equilibrated with column buffer (25 mM Na- HEPES, pH 
7.0, 300 mM NaCl, 1 mM PMSF, and 30 mM imidazole). Beads were washed thoroughly with 
column buffer and washing buffer (25 mM Na- HEPES, pH 7.0, 300 mM NaCl, 1 mM PMSF, 
and 70 mM imidazole), and eluted with elution buffer (25 mM Na-HEPES, pH 7.0, 300 mM 
NaCl, 1 mM PMSF, 100 mM EDTA, and 200 mM imidazole). Different eluents were checked 
by 12% SDS-PAGE. After dialysis and concentrating, protein concentration was determined by 
Bradford assay. Active flag-tagged human recombinant PRMT5/MEP50 was purchased from 
BPS Bioscience, Inc. 
5.4.4. Radioactive methylation assays 
The methylation assays of different H4 peptide substrates were performed using 14C-
isotope labeled AdoMet at 30°C. The typical reaction buffer contained 50 mM HEPES (pH=8.0), 
10 mM NaCl and 1 mM DTT. Peptide substrate and [14C]-AdoMet were preincubated in the 
reaction buffer for 5 min prior to the initiation of methyl transfer reaction by the addition of 
PRMT. The reaction time was controlled under initial condition so that the typical reaction yields 
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were within 15%. The reaction was quenched either by spreading the reaction mixture onto P81 
filter paper disc (Whatman) or by mixing the reaction buffer with 5x protein-loading dye. For the 
filter-binding assay, the paper discs were washed with 50 mM NaHCO3 (pH 9.0) and air dried 
for 2 h, and then liquid scintillation was conducted to measure the amount of methylated 
products. For the gel-based assay, methylation mixtures were resolved on 16% SDS-PAGE and 
the gel was dried and exposed to phosphor film for at least 36 h in dark. The phosphorimage was 
scanned on Typhoon 9400 scanner and the amount of methylated products was quantitated with 
ImageQuant program (GE healthcare). Data of Km and kcat were obtained with the filter binding 
assay by measuring the initial velocity of reaction at varied concentrations of one substrate and 
fixed saturating concentration of the other substrate, and fitting the kinetic data with Michaelis-
Menton equation.  
The methylation assays were also conducted for histone H4 protein and reconstituted 
nucleosomes to confirm the effect of H4 acetylation on its methylation by PRMT1 and PRMT5. 
Recombinant human core histones were purchased from New England Biolabs and reconstituted 
nucleosomes were assembled using the EpiMark assembly kit. The protein substrate was 
incubated with acetyl-CoA (20 μM) in the absence or presence of p300 or MOF (0.4 μM) in the 
reaction buffer (50 mM HEPES (pH = 8.0), 50 mM NaCl, 1mM EDTA, and 0.5 mM DTT) at 
30°C for 10 min. Then [14C]-AdoMet (15μM) and PRMT1 (0.01 μM) or PRMT5 (0.1 μM) were 
added into the reaction mixture to initialize H4 methylation. The methylated protein was 
separated on SDS-PAGE (15 % for H4 protein and 17 % for nucleosome) and visualized by 
storage phosphor imaging. 
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5.4.5. Circular Dichroism (CD) measurement and analysis 
Secondary structures of unacetylated H4 peptide and tetraacetylated H4 peptide at 
different concentrations of TFE were studied with CD on a Jasco J-810 spectropolarimeter. A 1-
mm CD cell with 200 μL of peptide sample (in 20 mM Tris buffer, pH 7.4) with 0 ~ 80% of 
2,2,2-trifluoroethanol (TFE) was loaded to the CD spectrophotometer. Nitrogen pressure was 
kept constant around 100 kPA. CD spectra of peptides were scanned from 260 nm to 190 nm 
with standard sensitivity, 0.5 nm data pitch, 1 nm band width, 100 nm/min scanning speed, and 
10-time accumulation. The concentrations of peptides were selected to keep the negative peak 
value of ellipticity in-between -10 mdeg to -30 mdeg. CD spectra were saved as text file (Jasco 
1.30) and submitted to Dichroweb, an online server for protein Circular Dichroism spectra 
deconvolution (154). Dichroweb incorporates five open source algorithms (Contin-LL, Selcon 3, 
CDSSTR, VARSSLC, and K2d) to calculate protein secondary structure content. Of these five 
algorithms, Provencher & Glockner Method (Contin-LL) and Self Consistent Method (Selcon 3) 
were chosen to determine the percentage of secondary structural components (helix, strand, turn, 
and random coil) of each peptide sample.  
5.4.6. Structure simulation for the unacetylated and tetraacetylated H4 peptides 
The modeling was conducted on the Jaguar parallel machine at the Oak Ridge Leadership 
Computing Facility by using the AMBER suite of programs. The wild-type and tetraacetylated 
H4 peptide were parameterized using the Antechamber (157) program with BCC charges. His-18 
of the wild type peptide was recognized to be in the epsilon-protonation state through an H-bond 
network analysis carried out using the WHATIF server (158) 
(http://swift.cmbi.ru.nl/servers/html/index.html). The same protonation state was assigned to the 
histidine of the tetraacetylated peptide since the presence of non-standard acetylated lysine 
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residues prevented the use of WHATIF. Replica exchange (REMD) simulations have been 
performed with the Amber10 suite (159) of programs using the force field ff99SB (160) and the 
GB-neck solvent model (161) with a 0.2 M concentration of monovalent ions and a dielectric 
constant of 78.5 (corresponding to water). Both the wild type and the acetylated peptides 
underwent 200 steps of steepest descent minimization followed by 200 steps of conjugate 
gradient minimization. Twenty replicas of the minimized system were then created and gradually 
heated to their target temperatures in a short 1 ns NPT run using Langevin dynamics with a 
collision frequency of 1.0 ps-1. The temperatures of the replicas were chosen in geometric 
progression to ensure uniform exchange probability for all pairs of temperatures (the values for 
the temperature T (in K) was set to 300, 314, 330, 345, 362, 380, 398, 417, 437, 458, 480, 503, 
528, 553, 580, 608, 637, 668, 700 and 734). A 105 ns REMD simulation was then carried out: 
the first 5 ns of the simulation were discarded and analysis was performed on a set of 1976 
structures for the wild type and 1722 structures for the acetylated peptide, respectively. The 
structures, sampled at intervals of 50 ps along the T = 300 K trajectory, were then clustered using 
a quality threshold clustering algorithm (162). Secondary structure analysis was performed using 
the DSSP algorithm (156) 
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CHAPTER 6 
SUMMARY 
Posttranslational modifications (PTMs) are important strategies used by eukaryotic 
organisms to modulate their phenotypes. One of the well studied PTMs, arginine methylation, is 
catalyzed by protein arginine methyltransferases (PRMTs) with SAM as the methyl donor. The 
functions of PRMTs have been broadly studied in different biological processes and diseased 
states like cancer and heart disease, suggesting them as potential therapeutic targets, but the 
molecular basis for arginine methylation is not well defined. To unravel the molecular 
mechanism of arginine methylation and facilitate the rational design of PRMT inhibitors, we 
explored several strategies to study the activity and inhibition of PRMT1, the predominant 
PRMT in mammalian cells.  
1. New fluorescent reporters were designed and applied to perform single-step analysis 
of substrate binding and methylation by PRMT1. Both fluorescence intensity and anisotropy 
of the two reporters, R4-FL and H4-FL, were shown to effectively manifest enzyme-substrate 
interactions, highlighting their application in investigating PRMT inhibitors. In particular, the 
methylation process of R4-FL can be directly studied using fluorescence intensity readout. By 
combining the fluorescent measurement with radioactive analysis, we determined that AMI-1 
inhibits PRMT1 activity through the mechanism of blocking peptide substrate binding. 
Furthermore, we showed that the fluorescence intensity of R4-FL is sensitive to the 
progression of both substrate binding and methylation, suggesting that it will be a useful 
fluorescent probe to investigate the transient kinetic mechanism of PRMT catalysis. Given 
that GAR motif-containing sequence is a common feature of many PRMT substrates,(23) R4-
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FL is not only a fluorescent reporter of PRMT1, but may also be applicable to other PRMT 
members. 
2. Malfunction of protein arginine methyltransferases (PRMTs) is correlated with many 
human diseases. Thus, small molecule inhibitors of protein arginine methylation are of great 
potential for therapeutic development. In out study, we have discovered a type of organic 
compounds containing naphthalene and sulfonyl pharmacophore components that inhibit PRMT 
activity in the micromolar range, whose inhibition mechanism is fundamentally distinct from the 
other PRMT inhibitors reported so far. The biochemical and biophysical data of representative 
compounds show that these inhibitors are competitive versus PRMT1 substrates (e.g., H4 and 
GAR peptides) and noncompetitive versus the methyl donor. Detailed studies illustrate that they 
directly target the peptide substrates instead of PRMT1, and the binding subsequently blocks the 
recognition of the substrates by the enzyme, which is largely responsible for the observed 
PRMT1 inhibition effect. We also show that the anti-parasitic drug suramin is also an effective 
arginine methylation inhibitor. These NS inhibitors will be useful chemical tools for mechanistic 
study of arginine methylation and other epigenetic modifications. Further, illumination of the 
inhibitory mechanism provides a new insight for understanding the pharmacological effect of 
these structurally unique molecules in biological systems. 
3. The biological functions of PRMTs have been shown to be involved in diverse 
biological processes and diseased states, yet the molecular basis for arginine methylation is 
unclear. In our study, we performed the transient-state kinetic analysis of PRMT1 catalysis. Our 
stopped-flow fluorescence data provide a detailed view of arginine methylation catalyzed by 
PRMT1. According to our result, the methyl transfer step is the major rate-limiting step which 
proceeds much slower than substrate association and product release. Binding of the cofactor 
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SAM/SAH appreciably affects the interaction between H4 peptide and the enzyme, probably due 
to a conformational change upon enzyme-cofactor complex formation. Importantly, the transient 
kinetics data reveal a conformational transition step following the substrate binding and prior to 
the chemical step. This protein isomerization likely reorganizes the active site of PRMT1, 
bringing the side-chain terminal nitrogen of H4R3 in close proximity to the reactive methyl 
group of SAM and facilitating the methyl transfer. These results provide new insights into the 
molecular mechanism of arginine methylation and the rational design of PRMT inhibitors.  
4. Epigenetic crosstalk has become a very popular research area recently. To dissect the 
interplaying relationship between different histone modification marks, we investigated how 
individual lysine acetylations and their different combinations at the H4 tail affect Arg-3 
methylation in cis. Our data reveal that the effect of lysine acetylation on arginine methylation 
depends on the site of acetylation and the type of methylation. While certain acetylations present 
a repressive impact on PRMT-1 mediated methylation (type I methylation), lysine acetylation 
generally is correlated with enhanced methylation by PRMT5 (type II methylation). In particular, 
Lys-5 acetylation inhibits activity of PRMT1 but promotes that of PRMT5. Furthermore, CD 
study and computer simulation demonstrate that hyperacetylation increases the content of 
ordered structures at the H4 tail region. These findings give new insights into the regulatory 
mechanism of Arg-3 methylation by H4 acetylation, and unravel that complex 
intercommunications exist between different PTM marks in cis. The divergent activities of 
PRMT1 and PRMT5 with respect to different acetyl-H4 substrates suggests that type I and type 
II PRMTs use distinct molecular determinants for substrate recognition and catalysis. 
Our data about the divergent impacts of acetylation on R3 methylation, e.g., K5 
acetylation represses while K16 acetylation enhances R3 asymmetric di-methylation, also 
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provide insights into the function of HATs. Many acetylated H4 isoforms, especially the one 
containing K16ac, favors R3 methylation by PRMT1. Therefore, certain H4 acetylation marks 
are compatible with type I methylation of R3. Recent MS analysis of H4 protein in 
differentiating human embryonic stem cells revealed that K16 was the most abundant acetylated 
residue and K16ac and K5ac rarely occurred on the same histone H4 molecule, indicating that to 
some extent, these two acetylations are mutually exclusive and likely have distinct functions 
(139). This is consistent with previous notions that K16 acetylation has distinct function from the 
acetylation of other lysine residues at the H4 tail, including K5ac (163, 164). Given that PRMT1-
mediated R3 methylation is associated with gene activation, it may be that K5 acetylation has 
repressive and K16 acetylation has activating function in gene regulation. Although histone 
acetylations are generally considered as gene activation marks, they might also be able to exhibit 
repressive function under certain contexts by fine tuning its site specificity at the histone tail with 
balanced usage of counteractive PTM marks such as K5ac and K16ac. Although a quantitative 
correlation of the exact linkage of individual H4 acetylation marks to transcriptional on/off status 
needs to be investigated in the future, a few studies indeed suggest that histone acetylation may 
possess repressive function in gene expression regulation in certain contexts (165-168). 
5. Indication from the assembled nucleosome methylation assay. 
In the study of accetylation effect on histone methylation, we found that H4 protein in the 
context of nucleosome or even in the presence of DNA (2:1 ratio as is in the nucleosome) was 
not appreciably methylated by PRMT1 or PRMT5 in our reaction conditions. The physiological 
substrate, nucleosome, has difficulty to be methylated by PRMT1/5. This important observation 
implicates that DNA (especially the unassembled free DNA) poses a physical barrier between 
nucleosomal histone and PRMTs, preventing the N-terminal tails of the core histones from being 
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recognized by PRMTs. In another way, the negatively charged DNA and the acidic suface 
grooves on PRMT1 may compete with each other to bind the the positively charged histones. In 
the cells, although the histone tails extend out from its nucleosome core and adopt a free, flexible 
sturcutre, they can also possibly interact with link DNA from another nucleosome or another 
chain. Quite likely, arginine methylation of the chromatin template by PRMTs would require 
additional accessory proteins or factors in vivo to release the interaction between DNA and 
histones and give access for PRMT binding. Another possibility is that the 5SrDNA used in our 
assay is not well-suited for nucleosome assembly. If we switch to another nuclear DNA fragment 
the methylation result could be different. This DNA effect should be further investigated. 
6. Salt effect on the interaction between NS-1 and H4-20. 
The NaCl salt effect on the interaction between H4-20 and NS-1 were tested with UV-Vis 
spectral chance and PRMT1 inhibition assay. From Figure SI-6, mixing of 5 μM H4-20 peptide 
induces a big change in the UV-Vis spectrum of 40 μM NS-1 (maximum absorption reduced 
nearly by half), but adding of 0 ~ 300 mM NaCl introduces very little change to the absorption of 
the mixture. Thus NaCl concentration has little effect on H4-20-NS-1 interaction. The inhibition 
effect of NS-1 on PRMT1 activity was also tested with varied NaCl concentration in the 
radioactive methylatioin assay (Figure SI-7). PRMT1 activity is negatively affected by NaCl 
concentration when it goes above 150 mM. If NS-1-H4-20 interaction is weakened by salt effect, 
we would expect to see an increase in PRMT1 activity when NaCl goes higher. Yet when NaCl 
ranges between 0 to 150 mM, the inhibition effect of NS-1 does not change much with NaCl 
concentration. Again this leads to the conclusion that the salt effect appears to be very minor, 
indicating that charge-change interaction is not the major driving force for H4-20-NS-1 
associtation. The hydrophobic interactions, H-bonding, or π-π stacking may play more important 
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roles here. As changing the substrate to H4(1-11) increased the IC50 of NS-1 significantly, we 
propose that the C-terminal and N-terminal residues are both required for efficient binding. 
According to the fluorescent titration with job’s method, NS-1 and H4(1-20) showed a 1:1 
binding ratio, thus the association should be specific instead of nonspecific charge-charge 
interaction. 
7. The enzyme-substrate interaction speculation from the modeled peptide and the crystal 
structure of PRMT1. 
We think that PRMT1 competes with DNA for binding to histones. Acid residues (20 
Asp and Glu) are predominant on the surface of PRMT1, forming several acid grooves which are 
supposed to generate an initial binding affinity for positively-charged substrates. Surface-
scannng mutagenesis study indicated that some of these negatively charged residues were 
important for substrate specificity (E47, E129, and E236), substrate binding (E46 and D51), 
dimerization/oligomerization, or transcription coactivator function (31). In the crystal structure, 
the electron densities of bound peptide substrates were broken into three separate fragments. 
Other than the arginine bound in the active site, the amino acid residues of the peptide were not 
clearly identified due to low resolution of side chain densities. A mixture of peptide binding 
modes was proposed from the three disconnected densities. The fact that multiple substrate 
binding grooves exist on the surface of PRMT1 may explain why PRMT1 methylates diverse 
protein substrates. The negatively charged C terminus is close to the active site and may play an 
important role for substrate binding or catalysis.  
Our biochemical data reveal that the impact of H4 acetylation on PRMT1-mediated R3 
methylation depends on the individual pattern of acetylation. The clear observation is that K5ac 
is the predominant modification mark that negatively impacts R3 methylation by PRMT1. The 
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lower kcat of H4K5ac methylation with regard to that of the wild type H4 suggests that the acetyl 
group on K5 produces a steric or hydrophobic hindrance in the active site, reducing the ability of 
PRMT1 in methylating H4R3. Interestingly, K16ac enhances R3 methylation, and to some 
degree antagonizes the effect of K5 acetylation. The observed acetylation effect suggests 
valuable clues about PRMT1-H4 interaction. It seems reasonable that K16ac affects Km, but not 
kcat, given the remoteness of this residue to R3 along H4 backbone. The prominent impact of 
K16 acetylation on R3 methylation is in good agreement with a previous study showing that the 
basic amino acid residues on the H4 tail distal from R3 (i.e., aa 16-20) interact with PRMT1 and 
contribute to substrate recognition (153). The crystal structure of PRMT1 highlights that an 
acidic area exists on the surface of PRMT1 (80) and suggests that positive charges of substrates 
are needed for binding to the enzyme. Here, our data demonstrate that electrostatic interaction 
does not seem to be the sole factor determining the PRMT1⎯substrate interaction since K16 
acetylation favors the methylation at R3. Upon tetra-acetylation, the structural modeling shows 
that H4 tail forms a more regular and bended conformation, likely bringing K16 closer to the 
target arginine and affecting the peptide binding with PRMT1. The extra acetyl group on K16 
may increase the hodrophobic contact or provide one more H-bond to a PRMT1 binding groove 
compared to the unacetylated, extended H4 peptide, thus lowering the Km. 
On the other hand, the acetylation effect on R3 methylation is quite opposite for PRMT5 
catalysis. We propose that PRMT5 likely has a larger binding pocket connected with the active 
site than PRMT1 to accommodate the acetyl group on Lys 5 close to Arg 3. This acetyl group 
may provide more hydrophobic or H-bond interaction with PRMT5 to increase its binding 
affinity. Thus compared with wild-type H4(1-20), H4K5ac become a better substrate for PRMT5 
and a worse substrate for PRMT1. 
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An effort is put to gain the crystal structure of PRMT1 fused with H4(1-20) to analyze 
the detailed binding mode. 
8. A discussion of type I and type II PRMT catalytic mechanism and a summary of how 
our discovery fits into the context of current understanding of arginine methylation.  
So far the only proposed catalytic mechanism of PRMT1 according to its crystal structure 
is that the two invariant active site glutamates fix the positive charge on the guanidine group on 
the δ and one of the ω nitrogens, so that the lone pair of electrons left on the other ω nitrogen can 
attack the active methylsulfonium group of SAM in close proximity. The attacking guanidine 
nitrogen is deprotonated by a His-Asp relay system. Possibly an active site structural 
rearrangement can help stablize the positively charged transition state, lowering the energy gap 
between the ground state and the transition state thus facilitating the reaction. The active site pH 
environment is important for catalysis, which puts electrostatic and steric requirements for the 
residues besides the target arginine. The detailed catalytic mechanism of type II PRMTs is still 
unkown due to lack of crystal structure of the enzyme-substrate-cofactor ternary complex. 
Recently the structure of C. elegans PRMT5 (CePRMT5) with bound SAH was reported. The 
mutagenesis study suggested that a conserved phenylalanine (Phe 379 for CePRMT5) in the 
active site of PRMT5 is critical for directing the symmetric di-methylation, as mutating of Phe 
379 to methionine (as in PRMT1) led to genetration of both symmetric and asymmetric 
dimethylated arginines. (17) Thus type I and type II PRMTs are likely to share a similar catalytic 
mechanism with different active site steric groups. Phe 379 is located on helix αA which 
becomes more structured upon the cofactor binding. The steric constraint placed by Phe 379 and 
possibly other residues should be important for PRMT5 product specificity. Yet we still don’t 
know exactly how the target arginine is bound in the active site (defined by E499, E508, F379, 
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K385, S503, and S669 in CePRMT5). It is possible that the two essential acidic residues (E499 
and E508) bind to the guanidinium δ and ω nitrogens in a similar manner as for PRMT1 to 
facilitate the methyl transfer. But after one methyl group is added, there is not enough space for 
the same ω nitrogen to accept another methyl group due to steric hindrance produced by Phe 
379, etc. So the monomethylated arginine has to rotate the side chain and likely rebind to another 
enzyme active site with switched positions of the two ω nitrogens for the free one to get 
methylated. Therefore, with the steric restriction in the active site, type II PRMTs can only 
catalyze the formation of symmetrically dimethylated arginines. But with a methionine in the 
position of the conserved phenylalanine, PRMT1 has a more flexible active site structure to 
accommodate two methyl groups on one ω nitrogen. Furthermore, from the above point of view, 
type II PRMTs are more likely to follow a distributive mechanism rather than a processive 
mechanism, similar as what we experimentally suggested for PRMT1.  
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Figure 6.1. The active site of PRMT5 (PDB 3UA3). 
Our kinetic data suggests that PRMT1 has to form a ternary complex with the substrate 
and the cofactor to transfer the methyl group. The catalytic mechanism is by bringing the two 
substrates in close proximity to facilitate the nucleophilic attack. The transient state kinetic data 
indicate that PRMT1 transfers two methyl groups following a distributive mechanism, that the 
chemical step of methyltransfer is rate-limiting, that cofactor binding causes an enzyme 
conformational change which increases its affinity for the substrate, and that substrate 
association leads to another conformational transition that likely covers the active site and brings 
the target arginine closer to the active methyl group of SAM for the nucelophilic attack. This 
may be acomplished by movement of the double-E loop connecting strand β4 and helix αD 
towards the target arginine of the peptide to bury it in the active site. To confirm these 
hypotheses, the crystal structures of the apo enzyme, the holoenzyme and the enzyme-cofactor-
substrate ternary complex should be compared. 
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APPENDIX 
Table SI-1. Inhibitory data of the fifty top-ranked compounds obtained from the 
virtual screening. In a typical assay, the reactions were carried out at 30°C with 0.1 μM of 6x-
rPRMT1, 5 μM of [14C]-AdoMet, and 2 μM of H4(1-20), in the presence of 100 μM of 
individual inhibitors. 
Compound ID Retained fractional 
activity of PRMT1 
Compound ID Retained fractional 
activity of PRMT1 
7395064 100  6117046 100 
5310809 100 7736131 100 
5794588 100 RJC 03491 100 
6877387 103 7558583 100 
6381790 98 5650276 93 
5839065 99 5839747 98 
6278455 91 5767214 100 
7848611 95 7071534 100 
5689130 100 6715339 100 
5838031 100 HTS 06914 100 
6244071 100 5845246 100 
6274859 100 JFD 00459 100 
6300962 120 6764997 99 
5718222 100 7340109 98 
6944291 100 5837758 108 
7245849 100 5839847 100 
5755262 100 7730013 121 
6097286 100 6911199 94 
7786009 120 5706616 100 
5836899 100 6746073 100 
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CD 10984 100 7789764 100 
SEW 03621 100 5847891 100 
5843933 90 6722670 92 
5688743 100 KM 08497 100 
6498204 100 2 80 
  
 
Table SI-2. IC50 of selected compounds for the inhibition of GST-hPRMT1. 
Radioactive methylation assay conditions were the same as described for the inhibition of His6x-
rPRMT1, except for longer reaction time. The typical reaction mixture contained 2 μM of H4(1-
20), 5 μM of [14C]-AdoMet, 0.1 μM of GST-hPRMT1, and increasing concentrations of 
individual inhibitor.  
 
compound # IC50 (μM) to GST-hPRMT1 
3 12.9 ± 0.2 
4 50.5 ± 0.5 
5 68.2 ± 1.0 
6 121.7 ± 7.8 
stilbamidine 56.6 ± 0.6 
1 91.2 ± 4.9 
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Figure SI-1. Structures and inhibition data of the rest of selected analog compounds. 
The inhibition assays were performed using His6x-rPRMT1 (0.1 μM), [14C]-AdoMet (5 μM), 
and H4(1-20) (2 μM). The potencies of these compounds are much weaker than compounds 
3→11.c 
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Figure SI-2. Fluorescent competitive binding of 3 to R4-FL. (a) Fluorescence 
anisotropy (524 nm) of R4-FL solution at different concentrations of PRMT1. The concentration 
of R4-FL was fixed at 0.2 μM. (b) Fluorescence anisotropy (524 nm) of R4-FL and PRMT1 
complex at different concentrations of 3. The total concentration of R4-FL and PRMT1 was 0.2 
μM and 2.0 μM respectively.  
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Figure SI-3. Kinetic analysis of 6 in the inhibition of PRMT1 plotted as double-
reciprocal plots. a. Inhibition pattern of 6 at fixed [14C]-AdoMet (5 μM) and varied H4(1-20) 
concentraions. The concentration of 6 was selected at 0 μM (♦), 50 μM (■), 100 μM (▲) and 
150 μM (●) respectively. b. Inhibition pattern of 6 at fixed H4(1-20) (2 μM) and varied [14C]-
AdoMet concentraions. The concentration of 6 was fixed at 0 μM (♦), 50 μM (■) and 100 μM 
(▲) respectively. 0.03 μM of His6x-rPRMT1 was added in all these assays.   
 
 
 
 
 
 
 
 
 
 
 
Figure SI-4. Stilbamidine and 6 compete with the substrate for binding to PRMT1. 
Fluorescence anisotropy (524 nm) of R4-FL─PRMT1 complex at different concentrations of 
stilbamidine (a) or 6 (b) was measured. The concentration of R4-FL and PRMT1 was fixed at 0.2 
μM and 2.0 μM, respectively, for both titrations. 
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Figure SI-5. CD study of H4(1-20) association with 3. 100 μM of H4(1-20) was titrated 
with 0 μM (∆), 100 μM (♦), and 200 μM (●) of 3 in 10 mM of Tris buffer (pH 7.4). CD 
spectrum change of H4(1-20) was monitored. The secondary structural data cannot be analyzed 
due to the formation of precipitate (H4(1-20) – compound 3 complex). 
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Figure SI-6. Salt effect on the UV-Vis spectrum of NS-1▬H4-20 complex. 40 μM 
NS-1 and 5 μM H4-20 were mixed in the reaction buffer (50 mM HEPES (pH 8.0), 1 mM 
EDTA, 0.5 mM DTT) containing different concentrations of NaCl (0, 15, 75, 150, 300 mM). The 
UV-Vis spectra (700 nm ~ 280 nm) were taken on a Shimadzu UV-1700 spectrophotometer. 1. 
Reaction buffer; 2. 40 μM NS-1 in the reaction buffer; 3. 40 μM NS-1 + 5 μM H4-20 + 0 mM 
NaCl; 4. 40 μM NS-1 + 5 μM H4-20 + 15 mM NaCl; 5. 40 μM NS-1 + 5 μM H4-20 + 75 mM 
NaCl; 6. 40 μM NS-1 + 5 μM H4-20 + 150 mM NaCl; 7. 40 μM NS-1 + 5 μM H4-20 + 300 mM 
NaCl. 
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Figure SI-7. Salt effect on the inhibition of NS-1 on PRMT1 activity. 2 μM H4-20 and 
5 μM 14C-SAM were mixed with 20 μM NS-1 in the reaction buffer (50 mM HEPES (pH 8.0), 1 
mM EDTA, 0.5 mM DTT) containing different concentrations of NaCl (0, 18.75, 37.5, 75, 150, 
300 mM). 0.1 μM PRMT1 was added to initiate the methyltransfer reaction which lasted for 8 
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min at 30 °C. The reaction was quenched by loadint the mixture onto P81 paper and the products 
were quantified by liquid scintillation. 
 
 
substrate k1/min‐1 *  M‐2 k2/min‐1 *  M‐2 P1/uM peptide/uM SAM/uM
H4(1‐20) 0.076 ± 0.004 0.23 ± 0.03 0.4 2 15
KRKK 0.010 ± 0.00077 0.013 ± 0.0013 1 5 30
KRK 0.0031 ± 0.00026 0.0044 ± 0.00052 2 5 30
H4(1‐11) 0.00031 ± 0.000011 0.00063 ± 0.000039 2 5 30
R1 0.000011 ± 0.00000031 0.000028 ± 0.0000015 5 5 50
 
Figure SI-8. Relative abundance of peptide changes as a function of time during the 
methylation reaction by rPRMT1. Data was derived from relative intensity of peaks in 
MALDI-MS analysis. 
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Figure SI-9. Scheme of the radioactive HMT assay.  
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Figure SI-10. Sequential Bi-substrate Binding Model of PRMT1 with H4 and SAM. 
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